ClinicaPublication

Home › Books › DNB Nuclear Medicine › Previous-year questions

Free question list · June 2020 to December 2025

DNB Nuclear Medicine previous-year questions (2020–2025)

All 297 DNB Nuclear Medicine theory questions from June 2020 to December 2025, topic-wise and session-wise, with how often each one has been asked. Use the list to find the high-yield topics, then read the solved answers in our printed book.

Get the solved bookRead free sample (PDF)

Most-asked DNB Nuclear Medicine questions

These questions have been set three times or more since June 2020. The number shows how many times each was asked.

  1. Parathyroid localisation — SPECT, PET (choline) & 4D-CT 8×Volume 2 · Part 7 · Thyroid & Parathyroid Imaging
  2. Myocardial viability — techniques, tracers & PET protocol 8×Volume 2 · Part 8 · Nuclear Cardiology
  3. FAPI imaging & theranostics 8×Volume 2 · Part 18 · Recent Advances: Novel Tracers & Molecular Targets
  4. PET crystals — BGO, LSO, LYSO comparison 7×Volume 1 · Part 2 · Radiation Detection & Instrumentation
  5. Tests of significance — t-test, chi-square, McNemar, ANOVA 7×Volume 1 · Part 5 · Biostatistics & Research Methodology
  6. Movement disorders & Parkinsonism — NM imaging 7×Volume 2 · Part 6 · Neurology
  7. Epilepsy — PET/SPECT & lesion imaging 7×Volume 2 · Part 6 · Neurology
  8. Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine) 7×Volume 2 · Part 16 · Neuroendocrine Tumours & PET/CT Oncology
  9. Alpha emitters & targeted alpha therapy 7×Volume 2 · Part 17 · Radionuclide Therapy & Theranostics
  10. Interaction of radiation with matter 6×Volume 1 · Part 1 · Basic Nuclear Physics
  11. HVL & TVL 6×Volume 1 · Part 1 · Basic Nuclear Physics
  12. Attenuation correction (PET/CT, SPECT/CT, PET/MR) 6×Volume 1 · Part 2 · Radiation Detection & Instrumentation
  13. FDG synthesis & quality control 6×Volume 1 · Part 4 · Radiopharmacy & Radiochemistry
  14. Sentinel node — radiopharmaceuticals & techniques 6×Volume 2 · Part 14 · Lymphatic System & Sentinel Node
  15. Insulinoma & functional pancreatic NETs — imaging (incl. exendin) 6×Volume 2 · Part 16 · Neuroendocrine Tumours & PET/CT Oncology
  16. Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST 6×Volume 2 · Part 16 · Neuroendocrine Tumours & PET/CT Oncology
  17. Brain tumours — PET/SPECT tracers & recurrence 6×Volume 2 · Part 16 · Neuroendocrine Tumours & PET/CT Oncology
  18. RAI-refractory DTC — definition, diagnosis & management 6×Volume 2 · Part 17 · Radionuclide Therapy & Theranostics
  19. PRRT — principles, protocol, indications & adverse effects 6×Volume 2 · Part 17 · Radionuclide Therapy & Theranostics
  20. Transient & secular equilibrium 5×Volume 1 · Part 1 · Basic Nuclear Physics
  21. Radiation & tissue weighting factors (ICRP 60 vs 103) 5×Volume 1 · Part 1 · Basic Nuclear Physics
  22. Gas-filled detectors — principle, regions & ionisation chamber 5×Volume 1 · Part 2 · Radiation Detection & Instrumentation
  23. Collimators — types & principles (SPECT vs PET collimation) 5×Volume 1 · Part 2 · Radiation Detection & Instrumentation
  24. Digital PET (SiPM) 5×Volume 1 · Part 2 · Radiation Detection & Instrumentation

Topic-wise DNB Nuclear Medicine previous-year questions

Grouped the way the book is organised, 2 volumes and 18 parts. Open a part to see its questions, how often each was asked, and the session, paper, question number and marks.

Volume 1 — Basic Sciences: Physics, Instrumentation, Radiopharmacy, Radiobiology & Safety, Biostatistics

Part 1 · Basic Nuclear Physics22 questions
  1. Explain what is meant by binding energy of the nucleus. Explain the meaning of the terms:… 1×Dec 2021 · Paper I · Q1
  2. Niel Bohr's atomic model with diagram. 1×Jun 2023 · Paper I · Q5b
  3. Auger electrons & characteristic X-rays 3×Jun 2020 · Paper I · Q9a · Jun 2023 · Paper I · Q6a · Dec 2023 · Paper I · Q6a
  4. Isomeric transition, internal conversion & electron capture 3×Dec 2020 · Paper I · Q2a · Jun 2023 · Paper I · Q7d · Jun 2025 · Paper I · Q5b
  5. I-131 & iodine isotopes — production & decay scheme 2×Jun 2021 · Paper II · Q10 · Jun 2025 · Paper I · Q5a
  6. Mo-99 / Tc-99m — production & decay scheme 2×Jun 2020 · Paper I · Q1 · Dec 2024 · Paper I · Q5b
  7. Modes of radioactive decay 2×Jun 2021 · Paper I · Q9 · Dec 2022 · Paper I · Q1
  8. Define the following: Branching Ratio. 1×Dec 2020 · Paper I · Q9e
  9. Decay equation (N = N0e^-λt), half-life & mean life 4×Dec 2020 · Paper I · Q8 · Dec 2021 · Paper I · Q9a–b · Dec 2023 · Paper I · Q2a · Jun 2024 · Paper I · Q5
  10. Physical, biological & effective half-life 2×Jun 2022 · Paper I · Q10a · Jun 2025 · Paper I · Q1a
  11. Transient & secular equilibrium 5×Jun 2020 · Paper I · Q2 · Dec 2020 · Paper I · Q8 · Dec 2022 · Paper II · Q8 · Dec 2023 · Paper I · Q3 · Jun 2025 · Paper I · Q9b
  12. Interaction of radiation with matter 6×Dec 2020 · Paper I · Q7 · Jun 2022 · Paper I · Q2a–b · Dec 2022 · Paper I · Q2 · Dec 2023 · Paper I · Q1 · Jun 2024 · Paper I · Q1 · Dec 2024 · Paper I · Q1
  13. Bremsstrahlung 4×Jun 2020 · Paper I · Q9b · Dec 2020 · Paper I · Q2b · Dec 2022 · Paper I · Q5a · Jun 2025 · Paper I · Q3a
  14. Linear energy transfer (LET) & Bragg peak 4×Dec 2020 · Paper I · Q9d · Jun 2023 · Paper I · Q7c · Dec 2024 · Paper I · Q2b · Dec 2024 · Paper I · Q5a
  15. Cerenkov radiation & Cerenkov luminescence imaging 3×Jun 2020 · Paper I · Q9c · Dec 2023 · Paper I · Q10b · Dec 2025 · Paper I · Q8b
  16. Pair production, Rayleigh scatter & photodisintegration 3×Jun 2023 · Paper I · Q5a · Jun 2025 · Paper I · Q10a · Dec 2025 · Paper I · Q8a
  17. Photoelectric & Compton effect 2×Jun 2023 · Paper I · Q7a · Jun 2024 · Paper I · Q9a
  18. Types of Neutron interactions with matter. 1×Jun 2023 · Paper I · Q6b
  19. HVL & TVL 6×Dec 2020 · Paper I · Q9c · Jun 2022 · Paper I · Q4 · Dec 2023 · Paper II · Q2a · Jun 2024 · Paper IV · Q8a · Dec 2024 · Paper I · Q6b · Dec 2025 · Paper I · Q7
  20. Specific gamma-ray constant 4×Jun 2020 · Paper I · Q7b · Dec 2022 · Paper I · Q7a · Jun 2023 · Paper I · Q7b · Dec 2024 · Paper I · Q2a
  21. Radiation & tissue weighting factors (ICRP 60 vs 103) 5×Dec 2020 · Paper I · Q6b · Jun 2023 · Paper I · Q9a · Dec 2023 · Paper I · Q7a · Jun 2024 · Paper IV · Q8b · Jun 2024 · Paper IV · Q9b
  22. Absorbed, equivalent & effective dose 3×Jun 2020 · Paper I · Q1 · Dec 2020 · Paper I · Q6a · Dec 2021 · Paper I · Q10a
Part 2 · Radiation Detection & Instrumentation47 questions
  1. Gas-filled detectors — principle, regions & ionisation chamber 5×Dec 2021 · Paper I · Q2a · Jun 2023 · Paper II · Q2 · Dec 2023 · Paper I · Q4 · Jun 2024 · Paper I · Q4 · Dec 2025 · Paper I · Q1
  2. GM counter (incl. quenching) 2×Dec 2022 · Paper II · Q3a · Dec 2023 · Paper I · Q6b
  3. What is radiation detector? Enumerate different types of detectors used in Nuclear medicine.… 1×Jun 2025 · Paper I · Q4
  4. PET crystals — BGO, LSO, LYSO comparison 7×Dec 2020 · Paper I · Q10 · Dec 2021 · Paper I · Q3c · Jun 2023 · Paper I · Q1 · Jun 2023 · Paper II · Q6a · Dec 2024 · Paper I · Q7a · Jun 2025 · Paper II · Q9a · Dec 2025 · Paper I · Q2
  5. Scintillation detectors — principle & types 2×Jun 2020 · Paper I · Q5a–b · Jun 2022 · Paper I · Q3b
  6. Solid-state / semiconductor detectors 4×Jun 2020 · Paper I · Q7a · Dec 2022 · Paper II · Q5b · Dec 2024 · Paper I · Q4 · Dec 2025 · Paper I · Q6
  7. CZT / solid-state cardiac cameras 2×Jun 2023 · Paper II · Q5b · Jun 2025 · Paper II · Q9b
  8. Dose calibrator — principle, QC & acceptance tests 4×Jun 2020 · Paper IV · Q4 · Dec 2021 · Paper I · Q2b · Dec 2022 · Paper II · Q3b · Jun 2025 · Paper II · Q1a
  9. Thyroid uptake probe 3×Jun 2020 · Paper II · Q1 · Dec 2022 · Paper II · Q7 · Dec 2024 · Paper II · Q3a
  10. Intra-operative gamma probe 2×Jun 2021 · Paper IV · Q4 · Dec 2022 · Paper II · Q4a
  11. Enlist and discuss various non-imaging equipments used for patient study on day-to-day basis… 1×Dec 2021 · Paper I · Q4a
  12. Describe various quality control parameters for well counter. 1×Jun 2025 · Paper I · Q6a
  13. Collimators — types & principles (SPECT vs PET collimation) 5×Jun 2021 · Paper I · Q10 · Dec 2022 · Paper I · Q8 · Dec 2023 · Paper II · Q1 · Dec 2024 · Paper I · Q3 · Dec 2025 · Paper I · Q4
  14. Phantoms in nuclear medicine 3×Dec 2021 · Paper I · Q5b · Dec 2022 · Paper II · Q5a · Dec 2024 · Paper II · Q2a
  15. Gamma camera electronics — preamplifier, amplifier & PHA 2×Jun 2025 · Paper II · Q10b · Dec 2025 · Paper I · Q5a
  16. SPECT / SPECT-CT quality control (NEMA) 2×Jun 2022 · Paper I · Q1b · Dec 2022 · Paper I · Q3
  17. Describe the role of crystal thickness on intrinsic spatial resolution and sensitivity for… 1×Jun 2021 · Paper I · Q1
  18. Working principle of SPECT Gamma Camera. 1×Jun 2022 · Paper I · Q1a
  19. Digital PET (SiPM) 5×Jun 2020 · Paper IV · Q8a · Jun 2021 · Paper I · Q3b · Jun 2021 · Paper IV · Q9b · Jun 2024 · Paper I · Q3 · Dec 2025 · Paper IV · Q4b
  20. Time-of-flight (TOF) PET 5×Dec 2020 · Paper I · Q4 · Jun 2021 · Paper IV · Q8 · Dec 2022 · Paper II · Q9b · Dec 2024 · Paper I · Q9b · Dec 2025 · Paper IV · Q4b
  21. Annihilation coincidence detection & PET events (CTR) 3×Jun 2020 · Paper I · Q9d · Dec 2021 · Paper I · Q3a · Dec 2024 · Paper I · Q9a
  22. PET/CT quality control 3×Jun 2021 · Paper I · Q5 · Jun 2024 · Paper I · Q6 · Dec 2025 · Paper I · Q9
  23. Total-body / long axial FOV PET 3×Jun 2020 · Paper IV · Q9a · Dec 2024 · Paper IV · Q8b · Dec 2025 · Paper IV · Q8
  24. Noise equivalent count rate (NECR) 2×Jun 2020 · Paper I · Q9e · Dec 2021 · Paper I · Q3b
  25. 2D PET versus 3D PET - advantage and disadvantages of each acquisition method. 1×Jun 2023 · Paper II · Q6b
  26. Attenuation correction (PET/CT, SPECT/CT, PET/MR) 6×Jun 2020 · Paper II · Q7a · Dec 2020 · Paper I · Q3 · Jun 2022 · Paper I · Q9 · Dec 2022 · Paper I · Q7b · Jun 2025 · Paper II · Q1b · Dec 2025 · Paper I · Q3
  27. PET/MRI — technology, configurations & physics 5×Jun 2021 · Paper IV · Q2 · Dec 2021 · Paper IV · Q1 · Dec 2024 · Paper II · Q1 · Jun 2025 · Paper II · Q7 · Dec 2025 · Paper IV · Q8
  28. PET/MRI — clinical applications vs PET/CT 4×Dec 2022 · Paper IV · Q7 · Dec 2023 · Paper IV · Q7 · Jun 2024 · Paper I · Q10 · Dec 2024 · Paper IV · Q7
  29. Filters in nuclear medicine imaging 5×Jun 2020 · Paper II · Q8 · Jun 2021 · Paper I · Q6 · Dec 2022 · Paper II · Q9a · Jun 2023 · Paper I · Q8a · Jun 2024 · Paper I · Q8
  30. FBP vs iterative reconstruction 4×Dec 2020 · Paper I · Q4 · Dec 2022 · Paper I · Q6 · Dec 2024 · Paper II · Q7 · Jun 2025 · Paper I · Q10b
  31. Compartmental models, discuss with suitable radionuclide example. 1×Jun 2020 · Paper I · Q3
  32. a) Methods of curve fittings. b) Explain Biexponential Curve fitting. 1×Jun 2021 · Paper I · Q2a–b
  33. DICOM & PACS. 1×Jun 2022 · Paper I · Q10b
  34. Nyquist Frequency. 1×Jun 2023 · Paper I · Q8b
  35. Statistical parametric mapping (SPM). 1×Jun 2025 · Paper I · Q9a
  36. Artefacts — SPECT, SPECT/CT & PET/CT 4×Dec 2020 · Paper II · Q10 · Jun 2023 · Paper I · Q2b · Dec 2023 · Paper III · Q6b · Jun 2025 · Paper II · Q10a
  37. Partial volume effect & recovery coefficient 4×Dec 2020 · Paper I · Q9a · Jun 2022 · Paper I · Q6 · Dec 2022 · Paper I · Q4a · Dec 2024 · Paper I · Q6a
  38. Dead time & its correction 2×Jun 2020 · Paper II · Q7b · Dec 2025 · Paper I · Q5b
  39. Spatial resolution — FWHM & factors affecting it 2×Dec 2020 · Paper I · Q9b · Dec 2021 · Paper I · Q5a
  40. SUV — definitions & factors affecting 3×Jun 2023 · Paper I · Q3 · Jun 2024 · Paper III · Q3b · Dec 2024 · Paper III · Q7a
  41. MTV & TLG 2×Dec 2020 · Paper IV · Q1a–b · Dec 2023 · Paper II · Q10a
  42. Quantitative PET parameters & factors affecting them 2×Jun 2020 · Paper II · Q4 · Dec 2022 · Paper III · Q4b
  43. CT & MRI — reconstruction & sequences 4×Jun 2023 · Paper I · Q2a · Jun 2023 · Paper I · Q9b · Jun 2023 · Paper III · Q9a · Jun 2024 · Paper I · Q10
  44. Beam hardening effect. 1×Dec 2022 · Paper I · Q4b
  45. Briefly describe the significance of: Slip ring technology. 1×Jun 2021 · Paper I · Q3a
  46. AI & machine learning in nuclear medicine 5×Jun 2020 · Paper IV · Q9b · Jun 2022 · Paper IV · Q5 · Jun 2023 · Paper IV · Q4a · Dec 2024 · Paper IV · Q9 · Dec 2025 · Paper IV · Q4a
  47. Radiomics 2×Jun 2020 · Paper IV · Q10a · Dec 2022 · Paper IV · Q10a
Part 3 · Radiobiology, Dosimetry & Radiation Safety25 questions
  1. Acute radiation syndrome 4×Jun 2020 · Paper IV · Q1b · Dec 2022 · Paper IV · Q3a · Jun 2023 · Paper IV · Q9a · Dec 2024 · Paper IV · Q3b
  2. RBE, OER & LET 3×Dec 2022 · Paper IV · Q3b · Jun 2024 · Paper I · Q9b · Dec 2024 · Paper IV · Q3a
  3. Stochastic vs deterministic effects 3×Jun 2020 · Paper IV · Q1a · Dec 2021 · Paper I · Q10b · Jun 2022 · Paper I · Q3a
  4. Biological dosimetry 2×Dec 2023 · Paper IV · Q8a · Jun 2024 · Paper IV · Q10
  5. Biological effects of radiation (somatic & genetic) 2×Dec 2023 · Paper IV · Q4b · Jun 2025 · Paper IV · Q4b
  6. Law of Bergonie and Tribondeau. 1×Dec 2023 · Paper IV · Q3a
  7. Internal dosimetry — MIRD & tumour dosimetry 3×Jun 2021 · Paper I · Q8 · Dec 2022 · Paper IV · Q1 · Jun 2025 · Paper I · Q8b
  8. Briefly elaborate on the principles and procedure of dosimetry in nuclear medicine… 1×Dec 2025 · Paper IV · Q5
  9. Personnel monitoring devices — TLD, OSL, pocket dosimeter 5×Dec 2020 · Paper I · Q1 · Dec 2021 · Paper II · Q6a–b · Dec 2022 · Paper II · Q6a · Dec 2023 · Paper II · Q7b · Dec 2024 · Paper II · Q3b
  10. Duties of the Radiological Safety Officer (RSO) 2×Dec 2023 · Paper IV · Q1 · Dec 2025 · Paper IV · Q3b
  11. NM facility & high-dose therapy ward design (AERB) 2×Dec 2024 · Paper IV · Q4a · Jun 2025 · Paper IV · Q3
  12. Hospital Radiation safety committee. 1×Jun 2020 · Paper IV · Q5a
  13. ICRP recommendations for dose limits for radiation professionals and general public. 1×Jun 2020 · Paper I · Q4a
  14. Swipe test. 1×Dec 2020 · Paper II · Q2b
  15. Classify the work places in nuclear medicine facility and explain briefly about work place… 1×Jun 2025 · Paper IV · Q2b
  16. Radioactive waste disposal 3×Jun 2020 · Paper IV · Q2 · Dec 2024 · Paper IV · Q1 · Dec 2025 · Paper IV · Q3a
  17. Delay Tank. 1×Jun 2020 · Paper IV · Q5b
  18. Radioactive spill — containment & management 3×Jun 2020 · Paper I · Q4b · Jun 2023 · Paper IV · Q1 · Dec 2025 · Paper IV · Q6b
  19. INES — International Nuclear & Radiological Event Scale 2×Jun 2021 · Paper II · Q3c · Dec 2023 · Paper IV · Q3b
  20. Lessons learnt from Fukushima Nuclear Accident. 1×Jun 2021 · Paper IV · Q3a
  21. Misadministration in nuclear medicine department and different steps undertaken to prevent it. 1×Dec 2023 · Paper II · Q4a
  22. Transport of radioactive material — regulations, packages & TI 5×Jun 2020 · Paper I · Q8 · Jun 2021 · Paper II · Q3a–b · Dec 2023 · Paper IV · Q4a · Dec 2024 · Paper IV · Q4b · Dec 2025 · Paper IV · Q6a
  23. Death of a patient after high-dose I-131 — handling 2×Jun 2020 · Paper IV · Q3 · Dec 2022 · Paper IV · Q2
  24. A recently married female, unaware of her pregnancy, received 5 mCi of I-131 activity… 1×Jun 2023 · Paper IV · Q9b
  25. Rules and recommendations in performing a NM procedure or therapy in a lactating mother. 1×Jun 2025 · Paper IV · Q1b
Part 4 · Radiopharmacy & Radiochemistry29 questions
  1. Cyclotron — working, types (negative vs positive ion) 3×Dec 2021 · Paper I · Q4b · Jun 2022 · Paper I · Q7 · Dec 2023 · Paper II · Q2b
  2. Lutetium-177 — production, decay scheme & uses 3×Jun 2023 · Paper II · Q8b · Dec 2023 · Paper I · Q5b · Dec 2025 · Paper II · Q5a
  3. Methods of radionuclide production (reactor, cyclotron, generator) 3×Jun 2021 · Paper II · Q9a · Dec 2021 · Paper I · Q8 · Jun 2023 · Paper II · Q1
  4. Carrier-free / no-carrier-added radionuclides 2×Jun 2021 · Paper II · Q9b · Dec 2024 · Paper II · Q2b
  5. Cyclotron-produced radionuclides (F-18, N-13 etc.) — production 2×Dec 2024 · Paper II · Q1 · Dec 2025 · Paper II · Q1
  6. Reactor-produced radionuclides 2×Dec 2022 · Paper II · Q4b · Jun 2025 · Paper II · Q3a
  7. Cyclotron-produced Technetium-99m - hype or hope in the era of frequent reactor short-downs. 1×Jun 2021 · Paper IV · Q3b
  8. Neutron Activation Analysis. 1×Jun 2025 · Paper I · Q3b
  9. Radionuclide generators — principles & types (incl. PET generators) 5×Jun 2020 · Paper II · Q3 · Dec 2020 · Paper II · Q3 · Dec 2021 · Paper II · Q8 · Dec 2022 · Paper II · Q1 · Dec 2025 · Paper II · Q8
  10. Ge-68/Ga-68 generator & Ga-68 radiochemistry 3×Jun 2022 · Paper II · Q9a–c · Jun 2023 · Paper II · Q8a · Dec 2024 · Paper II · Q8a
  11. Re-188 generator & Re-188 radiopharmaceuticals 3×Dec 2020 · Paper IV · Q2 · Jun 2021 · Paper II · Q4 · Jun 2024 · Paper II · Q1
  12. RBC labelling — methods & factors 3×Dec 2022 · Paper II · Q10 · Dec 2024 · Paper II · Q6b · Dec 2025 · Paper II · Q4b
  13. Bifunctional chelators 2×Dec 2020 · Paper II · Q7 · Jun 2024 · Paper IV · Q5
  14. What is the difference between radiochemical and radiopharmaceutical? Explain with example… 1×Jun 2021 · Paper II · Q2
  15. Routes of administration of radiopharmaceuticals with examples 1×Jun 2020 · Paper II · Q2
  16. Enumerate the SPECT radiopharmaceuticals requiring heating/boiling in their preparation and… 1×Jun 2025 · Paper II · Q2b
  17. FDG synthesis & quality control 6×Jun 2020 · Paper II · Q5 · Jun 2021 · Paper II · Q1 · Jun 2022 · Paper II · Q8b · Jun 2023 · Paper II · Q5a · Dec 2023 · Paper II · Q6 · Jun 2025 · Paper II · Q8a
  18. LAL & rabbit pyrogen tests 2×Dec 2020 · Paper II · Q2a · Jun 2024 · Paper II · Q6a–b
  19. QC of Tc-99m radiopharmaceuticals — radionuclidic & radiochemical purity 2×Dec 2022 · Paper II · Q1 · Dec 2023 · Paper II · Q5
  20. Radiopharmaceutical QC — physicochemical & biological tests 2×Jun 2022 · Paper II · Q10 · Dec 2025 · Paper II · Q7
  21. Molybedenum Breakthrough tests. 1×Dec 2021 · Paper II · Q4c
  22. Copper radionuclides (Cu-64/Cu-67) & copper theranostics 5×Dec 2022 · Paper IV · Q8 · Jun 2024 · Paper II · Q3 · Jun 2024 · Paper IV · Q9a · Dec 2024 · Paper IV · Q5a · Dec 2025 · Paper II · Q3
  23. Ga-68 radiopharmaceuticals — range & applications 4×Dec 2022 · Paper II · Q6b · Jun 2023 · Paper IV · Q4b · Jun 2025 · Paper II · Q2a · Dec 2025 · Paper II · Q3
  24. Iodine-124 2×Jun 2023 · Paper II · Q7a · Dec 2025 · Paper II · Q6a
  25. Zirconium-89 2×Jun 2025 · Paper II · Q6b · Dec 2025 · Paper II · Q6b
  26. Describe various long-lived positron emmiters whose half-lives are more than 2 hours with… 1×Jun 2024 · Paper II · Q2
  27. Name various peptide-based radiopharmaceuticals and describe one in details. 1×Dec 2020 · Paper II · Q8
  28. Terbium-152. 1×Jun 2024 · Paper II · Q10a
  29. List out ultrashort lived PET radiopharmaceutical and their clinical applications. 1×Jun 2025 · Paper II · Q4a
Part 5 · Biostatistics & Research Methodology12 questions
  1. RCT & clinical trial design 5×Jun 2020 · Paper I · Q6b · Jun 2021 · Paper I · Q7b · Dec 2023 · Paper I · Q8 · Jun 2024 · Paper I · Q7a · Jun 2025 · Paper I · Q7a–b
  2. Case-control study design 2×Jun 2021 · Paper I · Q7a · Dec 2021 · Paper I · Q6b
  3. Thesis protocol & ethics committee 2×Jun 2023 · Paper I · Q4a · Dec 2023 · Paper I · Q5a
  4. Discuss the various phases of clinical trial. 1×Dec 2022 · Paper I · Q10
  5. Tests of significance — t-test, chi-square, McNemar, ANOVA 7×Jun 2021 · Paper I · Q4 · Dec 2021 · Paper I · Q6a · Jun 2022 · Paper I · Q5a · Dec 2022 · Paper I · Q9a · Dec 2024 · Paper I · Q10a–b · Jun 2025 · Paper I · Q6b · Dec 2025 · Paper I · Q10b
  6. Distributions — Gaussian, Poisson, binomial 3×Jun 2022 · Paper I · Q5b · Dec 2023 · Paper I · Q7b · Dec 2024 · Paper I · Q10c–d
  7. Type I/II errors, null hypothesis & sample size 2×Dec 2020 · Paper I · Q5 · Jun 2023 · Paper I · Q10a–b
  8. a) Define an error in counting statistics. b) Enumerate the sources of error in a counting… 1×Jun 2025 · Paper I · Q2a–c
  9. Forest Plot. 1×Dec 2023 · Paper I · Q9a
  10. Kaplan Meier survival analysis. 1×Dec 2022 · Paper I · Q9b
  11. Enumerate measures of variability and describe them. 1×Dec 2023 · Paper I · Q10a
  12. ROC curve 4×Jun 2020 · Paper I · Q6a · Dec 2023 · Paper I · Q9b · Jun 2024 · Paper I · Q7b · Dec 2025 · Paper I · Q10a

Volume 2 — Clinical Nuclear Medicine, PET/CT Oncology & Radionuclide Therapy

Part 6 · Neurology10 questions
  1. Amyloid & tau PET imaging 5×Jun 2020 · Paper II · Q6b · Dec 2020 · Paper IV · Q5a · Jun 2021 · Paper IV · Q10a · Dec 2021 · Paper IV · Q3a · Jun 2025 · Paper II · Q6a
  2. Dementia — FDG patterns (AD, DLB, FTD, rapidly progressive) 5×Dec 2020 · Paper IV · Q5b · Jun 2021 · Paper III · Q6a–c · Jun 2022 · Paper II · Q7b · Dec 2023 · Paper IV · Q10a · Jun 2024 · Paper III · Q9
  3. Multimodality imaging in the evaluation and management of Alzheimer's disease. 1×Jun 2023 · Paper IV · Q3
  4. Movement disorders & Parkinsonism — NM imaging 7×Dec 2020 · Paper III · Q2 · Jun 2021 · Paper IV · Q5a · Dec 2022 · Paper IV · Q6b · Jun 2023 · Paper III · Q8b · Dec 2023 · Paper II · Q8a–b · Dec 2023 · Paper III · Q9a–b · Dec 2025 · Paper III · Q5
  5. TRODAT / DAT SPECT 2×Jun 2020 · Paper III · Q5b · Dec 2021 · Paper II · Q4a
  6. Epilepsy — PET/SPECT & lesion imaging 7×Jun 2020 · Paper III · Q5a · Dec 2020 · Paper IV · Q10a–c · Jun 2021 · Paper III · Q6d · Dec 2021 · Paper III · Q4b · Jun 2022 · Paper II · Q7a · Dec 2024 · Paper III · Q8b · Dec 2025 · Paper III · Q5
  7. Role of PET in imaging of auto-immune encephalitis. 1×Jun 2023 · Paper IV · Q6a
  8. Diamox SPECT. 1×Jun 2023 · Paper III · Q5b
  9. Role of Nuclear Medicine in the evaluation of drug addiction. 1×Jun 2021 · Paper III · Q2a
  10. Radionuclide Cysternography. 1×Jun 2022 · Paper II · Q4a
Part 7 · Thyroid & Parathyroid Imaging15 questions
  1. Discuss the iodine cycle in human body. 1×Dec 2024 · Paper I · Q8
  2. What is Perchlorate discharge test? Why its use has been drastically reduced in current time? 1×Dec 2021 · Paper II · Q2b
  3. What is rhTSH? Discuss the approved indications of its use. 1×Dec 2021 · Paper II · Q2a
  4. Graves' disease — management (adult & paediatric) 4×Dec 2021 · Paper III · Q10 · Dec 2022 · Paper III · Q9 · Dec 2023 · Paper III · Q4 · Dec 2024 · Paper III · Q2
  5. Clinical activity scores in the management of Graves' ophthalmopathy. 1×Jun 2021 · Paper III · Q9b
  6. Define thyroid storm and enumerate its clinical management. 1×Jun 2023 · Paper III · Q4b
  7. Describe the causes of thyrotoxicosis. Discuss how to manage various thyroiditis. 1×Dec 2020 · Paper III · Q5
  8. AJCC 8th edition — DTC staging changes 2×Jun 2023 · Paper III · Q3b · Jun 2024 · Paper IV · Q1
  9. ATA guidelines for thyroid cancer (2015 → 2025) 2×Jun 2022 · Paper IV · Q4 · Dec 2025 · Paper IV · Q9b
  10. Thyroid cancer genetics & genomics 2×Dec 2020 · Paper III · Q4 · Dec 2025 · Paper III · Q4b
  11. Thyroid nodule — Bethesda & TI-RADS 2×Jun 2024 · Paper III · Q5a · Dec 2025 · Paper IV · Q2b
  12. Discuss the management of medullary carcinoma thyroid. 1×Dec 2024 · Paper III · Q1b
  13. Discuss in brief the different SPECT and PET tracers used for imaging thyroid neoplasms. 1×Dec 2024 · Paper III · Q1a
  14. Parathyroid localisation — SPECT, PET (choline) & 4D-CT 8×Dec 2020 · Paper II · Q5a · Jun 2021 · Paper II · Q6b · Dec 2021 · Paper III · Q7b · Jun 2022 · Paper III · Q7a–b · Dec 2022 · Paper IV · Q6a · Dec 2023 · Paper III · Q10a · Dec 2024 · Paper II · Q5 · Jun 2025 · Paper IV · Q4a
  15. Describe embryology, normal and ectopic anatomical locations of parathyroids. What are the… 1×Jun 2020 · Paper I · Q10
Part 8 · Nuclear Cardiology15 questions
  1. PET MPI tracers (incl. F-18 flurpiridaz) 5×Dec 2022 · Paper IV · Q4b · Dec 2024 · Paper II · Q4 · Dec 2024 · Paper IV · Q5b · Jun 2025 · Paper II · Q8b · Dec 2025 · Paper II · Q4a
  2. Cardiac stress — pharmacological & physical 4×Jun 2020 · Paper III · Q4b · Dec 2021 · Paper III · Q4a · Jun 2022 · Paper III · Q5a–c · Jun 2023 · Paper III · Q5a
  3. MPI tracers — SPECT (Tl-201, Tc-99m MIBI/tetrofosmin) 2×Dec 2021 · Paper II · Q7 · Dec 2023 · Paper II · Q9
  4. Discuss different types of cardiomyopathies. Describe Myocardial Perfusion SPECT in ischemic… 1×Jun 2021 · Paper IV · Q10b
  5. INOCA & MINOCAl. 1×Dec 2023 · Paper IV · Q5a
  6. Role of myocardial perfusion imaging in acute coronary syndrome. 1×Jun 2025 · Paper III · Q7a
  7. Myocardial viability — techniques, tracers & PET protocol 8×Jun 2020 · Paper II · Q9b · Jun 2021 · Paper III · Q10 · Jun 2022 · Paper II · Q6a–b · Dec 2023 · Paper III · Q8a · Jun 2024 · Paper III · Q8 · Dec 2024 · Paper II · Q8b · Jun 2025 · Paper III · Q7b · Dec 2025 · Paper II · Q10
  8. Myocardial blood flow & flow reserve — PET quantification 3×Dec 2022 · Paper III · Q5b · Jun 2023 · Paper IV · Q2 · Dec 2023 · Paper IV · Q6b
  9. Cardiac amyloidosis 3×Dec 2022 · Paper IV · Q4a · Jun 2024 · Paper IV · Q6b · Dec 2024 · Paper IV · Q10
  10. Cardiac sarcoidosis imaging 3×Jun 2020 · Paper II · Q9a · Dec 2023 · Paper II · Q10b · Jun 2024 · Paper II · Q5
  11. Cardiac arrhythmias — SPECT & PET 2×Jun 2023 · Paper IV · Q5a–b · Jun 2025 · Paper IV · Q6b
  12. Cardiac infection & inflammation imaging 2×Dec 2025 · Paper III · Q2 · Dec 2025 · Paper III · Q7b
  13. LV dyssynchrony 2×Jun 2020 · Paper III · Q4a · Dec 2020 · Paper IV · Q6
  14. Vascular imaging — atherosclerotic plaque & thrombus 2×Dec 2022 · Paper IV · Q9a · Jun 2025 · Paper III · Q9a
  15. Recent advances in nuclear cardiology techniques. 1×Jun 2021 · Paper II · Q8
Part 9 · Pulmonary2 questions
  1. Pulmonary embolism — V/Q (planar vs SPECT) vs CTPA 3×Dec 2022 · Paper III · Q2b · Jun 2023 · Paper III · Q2 · Jun 2025 · Paper III · Q10a
  2. Radiotracer agents used in ventilation scan. 1×Dec 2024 · Paper II · Q6a
Part 10 · Gastrointestinal & Hepatobiliary9 questions
  1. Neonatal jaundice & biliary atresia — hepatobiliary scintigraphy 3×Jun 2020 · Paper III · Q8a · Jun 2021 · Paper III · Q8 · Jun 2022 · Paper III · Q4b
  2. Cholecystagogues & interventions in hepatobiliary scintigraphy 2×Jun 2022 · Paper III · Q4a · Dec 2022 · Paper III · Q4a
  3. Sphincter of Oddi & gallbladder dyskinesia 2×Dec 2020 · Paper III · Q1a · Jun 2025 · Paper III · Q9b
  4. Hepatobiliary scintigraphy: Radiopharmaceuticals, clinical indications and advantages over… 1×Dec 2021 · Paper III · Q3
  5. Role of NM techniques in evaluation of liver transplant. 1×Jun 2025 · Paper III · Q8b
  6. GI bleeding & Meckel's scintigraphy 3×Dec 2021 · Paper III · Q7a · Dec 2022 · Paper III · Q3 · Dec 2023 · Paper III · Q5a
  7. Gastric emptying & oesophageal transit 3×Jun 2023 · Paper III · Q6b · Dec 2023 · Paper III · Q7b · Jun 2025 · Paper III · Q8a
  8. Peritoneal scintigraphy. 1×Jun 2023 · Paper III · Q7b
  9. Urea breath test. 1×Dec 2024 · Paper III · Q3b
Part 11 · Musculoskeletal11 questions
  1. Complex regional pain syndrome 2×Dec 2020 · Paper III · Q3a · Dec 2023 · Paper III · Q7a
  2. F-18 NaF PET 2×Dec 2020 · Paper II · Q1b · Jun 2021 · Paper III · Q1a
  3. Painful limp (child / adult) 2×Dec 2023 · Paper III · Q8b · Jun 2025 · Paper III · Q3a
  4. Sports injuries 2×Dec 2022 · Paper III · Q5a · Jun 2025 · Paper III · Q3b
  5. Tumour-induced osteomalacia 2×Dec 2022 · Paper IV · Q10b · Dec 2024 · Paper III · Q8a
  6. Bone scan findings in metabolic bone diseases. 1×Jun 2020 · Paper III · Q2a
  7. What are the benign tumous of bone simulating malignancy? Discuss the role of Nuclear Imaging… 1×Dec 2021 · Paper III · Q1
  8. Bone scintigraphy in: Diabetic foot. 1×Dec 2020 · Paper III · Q3b
  9. Describe the role of nuclear imaging in musculoskeletal diseases, particularly the non… 1×Jun 2021 · Paper III · Q3
  10. Role of nucelar medicine in orthopaedic implant related complications evaluation. How does it… 1×Jun 2023 · Paper III · Q8a
  11. Define Three phase bone scintigraphy, procedure and indications. Is pin-hole imaging still… 1×Jun 2024 · Paper III · Q1
Part 12 · Nephro-urology & Adrenal11 questions
  1. GFR — plasma sample & other methods 4×Jun 2023 · Paper III · Q7a · Dec 2024 · Paper III · Q7b · Jun 2025 · Paper I · Q8a · Dec 2025 · Paper III · Q3
  2. Renal radiopharmaceuticals — glomerular vs tubular (DTPA, EC, MAG3) 2×Jun 2020 · Paper II · Q10 · Jun 2021 · Paper III · Q1b
  3. Diuretic renography & hydronephrosis / obstruction 3×Dec 2022 · Paper III · Q2a · Jun 2025 · Paper III · Q1a · Dec 2025 · Paper III · Q3
  4. Paediatric UTI, VUR & DRCG 4×Jun 2022 · Paper II · Q5 · Jun 2023 · Paper III · Q6a · Dec 2023 · Paper III · Q5b · Jun 2025 · Paper III · Q1b
  5. Renal scintigraphy in a patient after kidney transplant. 1×Jun 2024 · Paper III · Q2
  6. Interventions in renal scintigraphy for renal artery stenosis. 1×Jun 2020 · Paper III · Q8b
  7. Testicular Imaging. 1×Dec 2021 · Paper II · Q9c
  8. Phaeochromocytoma / paraganglioma — genetics & imaging 3×Dec 2020 · Paper III · Q8 · Dec 2021 · Paper II · Q3 · Dec 2025 · Paper IV · Q10b
  9. Young hypertensive / hypertension — NM evaluation 3×Jun 2022 · Paper II · Q3a–b · Jun 2025 · Paper III · Q4a–b · Dec 2025 · Paper III · Q7a
  10. Adrenocortical imaging 2×Jun 2021 · Paper III · Q4a · Jun 2022 · Paper II · Q8a
  11. A young female is clinically and biochemically diagnosed as having Cushing's Syndrome. All… 1×Dec 2021 · Paper II · Q1
Part 13 · Infection & Inflammation7 questions
  1. Large-vessel vasculitis — PET (Takayasu, GCA, PETVAS) 4×Jun 2023 · Paper III · Q1 · Jun 2023 · Paper IV · Q8b · Dec 2023 · Paper III · Q10b · Jun 2024 · Paper IV · Q6a
  2. Infection & inflammation imaging — SPECT & PET tracers 3×Jun 2022 · Paper III · Q6b · Dec 2022 · Paper III · Q1 · Jun 2025 · Paper IV · Q7
  3. Fever of unknown origin — PET/CT 2×Jun 2022 · Paper III · Q6a · Jun 2023 · Paper III · Q1
  4. IgG4-related disease — PET/CT 2×Dec 2023 · Paper III · Q6a · Jun 2025 · Paper III · Q2a
  5. Labelled leukocyte imaging (incl. FDG-WBC PET) 2×Jun 2022 · Paper IV · Q10 · Jun 2023 · Paper II · Q10b
  6. Rheumatology & myositis — PET/CT 2×Dec 2023 · Paper IV · Q9a · Jun 2025 · Paper IV · Q9a
  7. Scintigraphic evaluation for the management of Tuberculosis. 1×Jun 2021 · Paper III · Q9a
Part 14 · Lymphatic System & Sentinel Node3 questions
  1. Sentinel node — radiopharmaceuticals & techniques 6×Jun 2020 · Paper IV · Q10b · Dec 2021 · Paper II · Q10 · Jun 2022 · Paper II · Q2a–c · Dec 2023 · Paper IV · Q8b · Jun 2024 · Paper III · Q7 · Dec 2024 · Paper II · Q10
  2. Axillary reverse mapping 2×Jun 2023 · Paper IV · Q10b · Jun 2025 · Paper IV · Q8b
  3. Lymphoscintigraphy & lymphoedema 2×Jun 2020 · Paper III · Q6 · Dec 2020 · Paper III · Q1b
Part 15 · Miscellaneous & Allied Subjects10 questions
  1. Nuclear medicine in emergencies 2×Jun 2021 · Paper II · Q6a · Dec 2024 · Paper III · Q3a
  2. Pharmacological interventions in NM studies 2×Jun 2022 · Paper III · Q9b · Dec 2023 · Paper III · Q3a
  3. Salivary gland scintigraphy 2×Jun 2020 · Paper III · Q2b · Jun 2022 · Paper II · Q4b
  4. Dacryoscintigraphy. 1×Jun 2025 · Paper III · Q2b
  5. Role of Nuclear Medicine in organ transplant evaluations. 1×Dec 2021 · Paper IV · Q3b
  6. Radioimmunoassay and IRMA. 1×Dec 2025 · Paper III · Q4a
  7. Contrast induced nephropathy (CIN). 1×Jun 2023 · Paper III · Q9b
  8. Draw the diagrams of Nephron and Neuron labelling the parts. 1×Jun 2023 · Paper I · Q4b
  9. Segmental anatomy of liver with diagram. 1×Jun 2025 · Paper I · Q1b
  10. Management of Supraventricular Tachycardia. 1×Dec 2024 · Paper III · Q10b
Part 16 · Neuroendocrine Tumours & PET/CT Oncology35 questions
  1. Insulinoma & functional pancreatic NETs — imaging (incl. exendin) 6×Dec 2020 · Paper II · Q9a · Dec 2021 · Paper III · Q2a · Dec 2021 · Paper IV · Q6a · Jun 2023 · Paper II · Q4 · Jun 2024 · Paper II · Q9 · Dec 2024 · Paper IV · Q6
  2. NET imaging — SPECT & PET tracers 4×Dec 2021 · Paper III · Q6a · Jun 2022 · Paper III · Q1a–b · Dec 2022 · Paper II · Q2 · Jun 2025 · Paper II · Q5
  3. NETPET score 3×Dec 2022 · Paper III · Q6a · Dec 2024 · Paper III · Q6b · Jun 2025 · Paper IV · Q8a
  4. WHO classification & grading of NETs 3×Dec 2020 · Paper III · Q9a · Jun 2021 · Paper III · Q4b · Dec 2023 · Paper III · Q2
  5. Lung NETs / carcinoids 2×Dec 2020 · Paper III · Q9b · Dec 2021 · Paper IV · Q7
  6. Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST 6×Jun 2020 · Paper III · Q9 · Dec 2021 · Paper IV · Q2 · Jun 2023 · Paper III · Q10a · Jun 2023 · Paper IV · Q8a · Dec 2023 · Paper IV · Q10b · Jun 2024 · Paper IV · Q4a
  7. Response evaluation criteria — RECIST, PERCIST, EORTC 4×Jun 2022 · Paper III · Q3 · Jun 2023 · Paper IV · Q7a · Dec 2024 · Paper III · Q5a · Dec 2025 · Paper III · Q8
  8. Reporting & data systems (RADS — PI-RADS, TI-RADS, etc.) 2×Dec 2023 · Paper IV · Q9b · Jun 2025 · Paper IV · Q9b
  9. Discuss various factors leading to False Positive and False Negative FDG PET/CT Imaging. 1×Jun 2024 · Paper III · Q3a
  10. Enumerate and classify radiopharmaceuticals used for tumor imaging. 1×Jun 2021 · Paper II · Q7a
  11. Brain tumours — PET/SPECT tracers & recurrence 6×Dec 2020 · Paper II · Q1a · Dec 2021 · Paper II · Q5a · Dec 2022 · Paper III · Q7 · Jun 2023 · Paper II · Q3 · Jun 2024 · Paper II · Q4 · Dec 2024 · Paper II · Q9
  12. Recent WHO classification of brain tumors. Discuss molecular markers and their implication in… 1×Dec 2020 · Paper III · Q10
  13. NSCLC — molecular landscape & targeted therapy 2×Jun 2021 · Paper III · Q7a · Jun 2023 · Paper IV · Q6b
  14. Role of PET/CT imaging in the management of Head & Neck squamous cell carcinomas. 1×Dec 2021 · Paper III · Q2b
  15. Mediastinal nodal stations. 1×Dec 2023 · Paper I · Q2b
  16. Role of PET/CT in staging and response assessment of non-small cell lung cancers. 1×Dec 2020 · Paper III · Q6
  17. Breast cancer — staging & PET/CT (NCCN, LABC) 3×Jun 2021 · Paper IV · Q7a · Jun 2023 · Paper III · Q4a · Jun 2025 · Paper III · Q6
  18. FES (fluoroestradiol) PET 2×Dec 2021 · Paper III · Q9a · Dec 2024 · Paper IV · Q8a
  19. Positron emission mammography (PEM) 2×Dec 2021 · Paper IV · Q4a · Jun 2022 · Paper IV · Q3a
  20. Triple-negative breast cancer 2×Dec 2020 · Paper IV · Q7 · Jun 2021 · Paper IV · Q7b
  21. Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine) 7×Dec 2020 · Paper II · Q5b · Jun 2022 · Paper II · Q1 · Jun 2022 · Paper IV · Q8a · Dec 2023 · Paper II · Q3 · Jun 2024 · Paper II · Q8 · Jun 2024 · Paper IV · Q3b · Dec 2025 · Paper II · Q2
  22. mCRPC — PET imaging & management 2×Dec 2020 · Paper III · Q7 · Dec 2021 · Paper III · Q8b
  23. PROMISE Criteria. 1×Jun 2024 · Paper IV · Q3a
  24. Staging of Adenocarcinoma of prostate as per AJCC 8th Edition. 1×Jun 2021 · Paper III · Q7b
  25. Compare and contrast the multiparametric-MR versus nuclear imaging in prostate cancer. 1×Dec 2020 · Paper IV · Q4
  26. Lymphoma — PET/CT staging, Deauville & response 3×Jun 2024 · Paper IV · Q4b · Dec 2024 · Paper III · Q6a · Dec 2025 · Paper III · Q9
  27. Multiple myeloma — PET/CT 3×Dec 2021 · Paper III · Q8a · Jun 2022 · Paper III · Q2 · Jun 2024 · Paper III · Q10a
  28. DLBCL vs. ALCL 1×Dec 2020 · Paper IV · Q8a
  29. Gynaecological malignancies — PET/CT 2×Jun 2020 · Paper III · Q7 · Jun 2024 · Paper III · Q6
  30. PET/CT Enteroclysis: Indications, technique and advantages. 1×Jun 2022 · Paper IV · Q1a
  31. Special techniques in PET/CT imaging in pelvic organ malignancies. 1×Jun 2022 · Paper IV · Q1b
  32. Neuroblastoma — imaging & management 2×Dec 2020 · Paper II · Q9b · Dec 2024 · Paper III · Q10a
  33. PET/CT-guided biopsy & interventions 5×Dec 2021 · Paper IV · Q5a · Jun 2023 · Paper IV · Q10a · Dec 2023 · Paper II · Q7a · Jun 2024 · Paper IV · Q7 · Dec 2025 · Paper IV · Q1a
  34. PET-CT in carcinoma of unknown primary. 1×Jun 2025 · Paper III · Q10b
  35. PET/CT in Radiotherapy Treatment Planning. What are its limitations? 1×Dec 2021 · Paper IV · Q8a
Part 17 · Radionuclide Therapy & Theranostics26 questions
  1. Paediatric DTC — management (incl. pulmonary metastases) 3×Jun 2020 · Paper III · Q1 · Dec 2021 · Paper III · Q5 · Jun 2025 · Paper IV · Q1a
  2. Role of External Radiation therapy in the management of thyroid cancer. 1×Jun 2022 · Paper IV · Q8b
  3. Preparations and precautions required for the high-dose radio-iodine therapy of a patient… 1×Jun 2023 · Paper III · Q3a
  4. RAI-refractory DTC — definition, diagnosis & management 6×Dec 2020 · Paper IV · Q9 · Jun 2021 · Paper III · Q2b · Dec 2021 · Paper IV · Q8b · Dec 2023 · Paper III · Q1 · Dec 2024 · Paper III · Q4 · Dec 2025 · Paper III · Q6
  5. TKIs in thyroid cancer (incl. trials) 4×Jun 2020 · Paper IV · Q6 · Jun 2021 · Paper IV · Q6 · Dec 2021 · Paper III · Q9b · Dec 2022 · Paper IV · Q5
  6. TENIS — evaluation & management 3×Jun 2024 · Paper III · Q5b · Jun 2025 · Paper IV · Q5b · Dec 2025 · Paper III · Q6
  7. COSMIC-311 trial 2×Jun 2021 · Paper IV · Q1b · Dec 2023 · Paper IV · Q5b
  8. Redifferentiation of Radioiodine refractory differentiated thyroid cancer for reapplication… 1×Jun 2022 · Paper IV · Q6
  9. PRRT — principles, protocol, indications & adverse effects 6×Jun 2020 · Paper III · Q3a · Dec 2022 · Paper III · Q10b · Dec 2023 · Paper III · Q2 · Jun 2024 · Paper IV · Q2b · Dec 2024 · Paper III · Q9 · Dec 2025 · Paper III · Q10a–c
  10. Nephroprotection in PRRT 3×Jun 2020 · Paper III · Q3b · Dec 2021 · Paper IV · Q10 · Jun 2023 · Paper III · Q10b
  11. Alpha vs beta vs Auger emitters for therapy 4×Jun 2021 · Paper II · Q3d · Jun 2022 · Paper I · Q8 · Dec 2023 · Paper II · Q4b · Dec 2025 · Paper IV · Q9a
  12. Theranostics — concept, pairs & future trends 2×Jun 2025 · Paper IV · Q2a · Dec 2025 · Paper II · Q9
  13. Ideal characteristics of therapeutic radionuclides. 1×Jun 2020 · Paper II · Q6a
  14. Alpha emitters & targeted alpha therapy 7×Dec 2020 · Paper II · Q6 · Dec 2020 · Paper IV · Q3 · Jun 2021 · Paper IV · Q5b · Dec 2021 · Paper I · Q7a · Dec 2021 · Paper IV · Q4b · Jun 2024 · Paper I · Q2 · Jun 2025 · Paper IV · Q5a
  15. Actinium-225 — decay scheme, production & nanogenerator 5×Dec 2021 · Paper I · Q7b · Dec 2022 · Paper I · Q5b · Jun 2023 · Paper II · Q7b · Dec 2024 · Paper I · Q7b · Dec 2025 · Paper II · Q5b
  16. Pb-212/Pb-203 & At-211 theranostics 2×Jun 2024 · Paper IV · Q2a · Dec 2025 · Paper IV · Q2a
  17. PSMA RLT trials — VISION, TheraP & ongoing trials 5×Jun 2021 · Paper IV · Q1a · Dec 2022 · Paper IV · Q9b · Jun 2023 · Paper IV · Q7b · Dec 2024 · Paper IV · Q2 · Dec 2025 · Paper IV · Q7
  18. Prostate cancer — treatment options & radionuclide therapies 2×Dec 2022 · Paper III · Q8 · Jun 2025 · Paper IV · Q10
  19. Describe indications, advantages and disadvantages of Lu-177 PSMA-617 and Ac-225 PSMA-617 in… 1×Jun 2022 · Paper IV · Q9
  20. Discuss the determinants and mechanisms of resistance for PSMA radioligand therapy in… 1×Dec 2023 · Paper IV · Q2
  21. Bone pain palliation radiopharmaceuticals 3×Dec 2020 · Paper II · Q4 · Dec 2022 · Paper III · Q10a · Jun 2023 · Paper II · Q9
  22. Radiosynovectomy 2×Dec 2021 · Paper III · Q6b · Jun 2024 · Paper II · Q7
  23. TACE vs TARE / SIRT 3×Dec 2020 · Paper IV · Q8b · Jun 2022 · Paper III · Q9a · Dec 2024 · Paper III · Q5b
  24. TARE / SIRT — indications, procedure & dosimetry 3×Jun 2020 · Paper III · Q10 · Dec 2021 · Paper IV · Q5b · Dec 2023 · Paper III · Q3b
  25. I-131 MIBG therapy — neuroblastoma, protocol & complications 3×Dec 2021 · Paper IV · Q9 · Jun 2022 · Paper III · Q8 · Jun 2025 · Paper III · Q5
  26. Radioimmunotherapy (RIT) 2×Jun 2021 · Paper III · Q5 · Jun 2022 · Paper IV · Q7b
Part 18 · Recent Advances: Novel Tracers & Molecular Targets8 questions
  1. FAPI imaging & theranostics 8×Jun 2020 · Paper IV · Q8b · Jun 2021 · Paper II · Q5 · Dec 2021 · Paper II · Q5b · Jun 2023 · Paper II · Q10a · Dec 2023 · Paper IV · Q6a · Jun 2024 · Paper III · Q4 · Dec 2024 · Paper IV · Q6 · Jun 2025 · Paper IV · Q6a
  2. F-18 FDOPA PET — clinical applications 5×Jun 2021 · Paper II · Q7b · Jun 2022 · Paper IV · Q2a · Dec 2022 · Paper III · Q6b · Jun 2025 · Paper II · Q4b · Dec 2025 · Paper IV · Q10a
  3. CXCR4 / Pentixafor imaging 4×Dec 2021 · Paper IV · Q6b · Jun 2022 · Paper IV · Q3b · Jun 2025 · Paper II · Q3b · Dec 2025 · Paper IV · Q1b
  4. Hypoxia imaging 4×Dec 2021 · Paper II · Q9b · Jun 2022 · Paper III · Q10a–b · Jun 2024 · Paper II · Q10b · Dec 2025 · Paper III · Q1a
  5. Angiogenesis imaging 3×Dec 2021 · Paper II · Q9a · Jun 2022 · Paper IV · Q2b · Dec 2025 · Paper III · Q1b
  6. Immuno-PET / antibody-based PET 2×Jun 2022 · Paper IV · Q7a · Jun 2024 · Paper III · Q10b
  7. Radio-receptor Imaging - strength and pitfalls. 1×Jun 2021 · Paper IV · Q9a
  8. Role of Nuclear Medicine in stem cell imaging. 1×Jun 2020 · Paper IV · Q7

DNB Nuclear Medicine question papers, session by session

The topics set in each exam session, paper by paper and in question order, latest first.

DNB Nuclear Medicine December 202562 questions

Paper I

  • Q1 — Gas-filled detectors — principle, regions & ionisation chamber
  • Q2 — PET crystals — BGO, LSO, LYSO comparison
  • Q3 — Attenuation correction (PET/CT, SPECT/CT, PET/MR)
  • Q4 — Collimators — types & principles (SPECT vs PET collimation)
  • Q5a — Gamma camera electronics — preamplifier, amplifier & PHA
  • Q5b — Dead time & its correction
  • Q6 — Solid-state / semiconductor detectors
  • Q7 — HVL & TVL
  • Q8a — Pair production, Rayleigh scatter & photodisintegration
  • Q8b — Cerenkov radiation & Cerenkov luminescence imaging
  • Q9 — PET/CT quality control
  • Q10a — ROC curve
  • Q10b — Tests of significance — t-test, chi-square, McNemar, ANOVA

Paper II

  • Q1 — Cyclotron-produced radionuclides (F-18, N-13 etc.) — production
  • Q2 — Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine)
  • Q3 — Copper radionuclides (Cu-64/Cu-67) & copper theranostics
  • Q3 — Ga-68 radiopharmaceuticals — range & applications
  • Q4a — PET MPI tracers (incl. F-18 flurpiridaz)
  • Q4b — RBC labelling — methods & factors
  • Q5a — Lutetium-177 — production, decay scheme & uses
  • Q5b — Actinium-225 — decay scheme, production & nanogenerator
  • Q6a — Iodine-124
  • Q6b — Zirconium-89
  • Q7 — Radiopharmaceutical QC — physicochemical & biological tests
  • Q8 — Radionuclide generators — principles & types (incl. PET generators)
  • Q9 — Theranostics — concept, pairs & future trends
  • Q10 — Myocardial viability — techniques, tracers & PET protocol

Paper III

  • Q1a — Hypoxia imaging
  • Q1b — Angiogenesis imaging
  • Q2 — Cardiac infection & inflammation imaging
  • Q3 — GFR — plasma sample & other methods
  • Q3 — Diuretic renography & hydronephrosis / obstruction
  • Q4a — Radioimmunoassay and IRMA.
  • Q4b — Thyroid cancer genetics & genomics
  • Q5 — Movement disorders & Parkinsonism — NM imaging
  • Q5 — Epilepsy — PET/SPECT & lesion imaging
  • Q6 — RAI-refractory DTC — definition, diagnosis & management
  • Q6 — TENIS — evaluation & management
  • Q7a — Young hypertensive / hypertension — NM evaluation
  • Q7b — Cardiac infection & inflammation imaging
  • Q8 — Response evaluation criteria — RECIST, PERCIST, EORTC
  • Q9 — Lymphoma — PET/CT staging, Deauville & response
  • Q10a–c — PRRT — principles, protocol, indications & adverse effects

Paper IV

  • Q1a — PET/CT-guided biopsy & interventions
  • Q1b — CXCR4 / Pentixafor imaging
  • Q2a — Pb-212/Pb-203 & At-211 theranostics
  • Q2b — Thyroid nodule — Bethesda & TI-RADS
  • Q3a — Radioactive waste disposal
  • Q3b — Duties of the Radiological Safety Officer (RSO)
  • Q4a — AI & machine learning in nuclear medicine
  • Q4b — Digital PET (SiPM)
  • Q4b — Time-of-flight (TOF) PET
  • Q5 — Briefly elaborate on the principles and procedure of dosimetry in nuclear medicine…
  • Q6a — Transport of radioactive material — regulations, packages & TI
  • Q6b — Radioactive spill — containment & management
  • Q7 — PSMA RLT trials — VISION, TheraP & ongoing trials
  • Q8 — Total-body / long axial FOV PET
  • Q8 — PET/MRI — technology, configurations & physics
  • Q9a — Alpha vs beta vs Auger emitters for therapy
  • Q9b — ATA guidelines for thyroid cancer (2015 → 2025)
  • Q10a — F-18 FDOPA PET — clinical applications
  • Q10b — Phaeochromocytoma / paraganglioma — genetics & imaging
DNB Nuclear Medicine June 202569 questions

Paper I

  • Q1a — Physical, biological & effective half-life
  • Q1b — Segmental anatomy of liver with diagram.
  • Q2a–c — a) Define an error in counting statistics. b) Enumerate the sources of error in a counting…
  • Q3a — Bremsstrahlung
  • Q3b — Neutron Activation Analysis.
  • Q4 — What is radiation detector? Enumerate different types of detectors used in Nuclear medicine.…
  • Q5a — I-131 & iodine isotopes — production & decay scheme
  • Q5b — Isomeric transition, internal conversion & electron capture
  • Q6a — Describe various quality control parameters for well counter.
  • Q6b — Tests of significance — t-test, chi-square, McNemar, ANOVA
  • Q7a–b — RCT & clinical trial design
  • Q8a — GFR — plasma sample & other methods
  • Q8b — Internal dosimetry — MIRD & tumour dosimetry
  • Q9a — Statistical parametric mapping (SPM).
  • Q9b — Transient & secular equilibrium
  • Q10a — Pair production, Rayleigh scatter & photodisintegration
  • Q10b — FBP vs iterative reconstruction

Paper II

  • Q1a — Dose calibrator — principle, QC & acceptance tests
  • Q1b — Attenuation correction (PET/CT, SPECT/CT, PET/MR)
  • Q2a — Ga-68 radiopharmaceuticals — range & applications
  • Q2b — Enumerate the SPECT radiopharmaceuticals requiring heating/boiling in their preparation and…
  • Q3a — Reactor-produced radionuclides
  • Q3b — CXCR4 / Pentixafor imaging
  • Q4a — List out ultrashort lived PET radiopharmaceutical and their clinical applications.
  • Q4b — F-18 FDOPA PET — clinical applications
  • Q5 — NET imaging — SPECT & PET tracers
  • Q6a — Amyloid & tau PET imaging
  • Q6b — Zirconium-89
  • Q7 — PET/MRI — technology, configurations & physics
  • Q8a — FDG synthesis & quality control
  • Q8b — PET MPI tracers (incl. F-18 flurpiridaz)
  • Q9a — PET crystals — BGO, LSO, LYSO comparison
  • Q9b — CZT / solid-state cardiac cameras
  • Q10a — Artefacts — SPECT, SPECT/CT & PET/CT
  • Q10b — Gamma camera electronics — preamplifier, amplifier & PHA

Paper III

  • Q1a — Diuretic renography & hydronephrosis / obstruction
  • Q1b — Paediatric UTI, VUR & DRCG
  • Q2a — IgG4-related disease — PET/CT
  • Q2b — Dacryoscintigraphy.
  • Q3a — Painful limp (child / adult)
  • Q3b — Sports injuries
  • Q4a–b — Young hypertensive / hypertension — NM evaluation
  • Q5 — I-131 MIBG therapy — neuroblastoma, protocol & complications
  • Q6 — Breast cancer — staging & PET/CT (NCCN, LABC)
  • Q7a — Role of myocardial perfusion imaging in acute coronary syndrome.
  • Q7b — Myocardial viability — techniques, tracers & PET protocol
  • Q8a — Gastric emptying & oesophageal transit
  • Q8b — Role of NM techniques in evaluation of liver transplant.
  • Q9a — Vascular imaging — atherosclerotic plaque & thrombus
  • Q9b — Sphincter of Oddi & gallbladder dyskinesia
  • Q10a — Pulmonary embolism — V/Q (planar vs SPECT) vs CTPA
  • Q10b — PET-CT in carcinoma of unknown primary.

Paper IV

  • Q1a — Paediatric DTC — management (incl. pulmonary metastases)
  • Q1b — Rules and recommendations in performing a NM procedure or therapy in a lactating mother.
  • Q2a — Theranostics — concept, pairs & future trends
  • Q2b — Classify the work places in nuclear medicine facility and explain briefly about work place…
  • Q3 — NM facility & high-dose therapy ward design (AERB)
  • Q4a — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q4b — Biological effects of radiation (somatic & genetic)
  • Q5a — Alpha emitters & targeted alpha therapy
  • Q5b — TENIS — evaluation & management
  • Q6a — FAPI imaging & theranostics
  • Q6b — Cardiac arrhythmias — SPECT & PET
  • Q7 — Infection & inflammation imaging — SPECT & PET tracers
  • Q8a — NETPET score
  • Q8b — Axillary reverse mapping
  • Q9a — Rheumatology & myositis — PET/CT
  • Q9b — Reporting & data systems (RADS — PI-RADS, TI-RADS, etc.)
  • Q10 — Prostate cancer — treatment options & radionuclide therapies
DNB Nuclear Medicine December 202463 questions

Paper I

  • Q1 — Interaction of radiation with matter
  • Q2a — Specific gamma-ray constant
  • Q2b — Linear energy transfer (LET) & Bragg peak
  • Q3 — Collimators — types & principles (SPECT vs PET collimation)
  • Q4 — Solid-state / semiconductor detectors
  • Q5a — Linear energy transfer (LET) & Bragg peak
  • Q5b — Mo-99 / Tc-99m — production & decay scheme
  • Q6a — Partial volume effect & recovery coefficient
  • Q6b — HVL & TVL
  • Q7a — PET crystals — BGO, LSO, LYSO comparison
  • Q7b — Actinium-225 — decay scheme, production & nanogenerator
  • Q8 — Discuss the iodine cycle in human body.
  • Q9a — Annihilation coincidence detection & PET events (CTR)
  • Q9b — Time-of-flight (TOF) PET
  • Q10a–b — Tests of significance — t-test, chi-square, McNemar, ANOVA
  • Q10c–d — Distributions — Gaussian, Poisson, binomial

Paper II

  • Q1 — PET/MRI — technology, configurations & physics
  • Q1 — Cyclotron-produced radionuclides (F-18, N-13 etc.) — production
  • Q2a — Phantoms in nuclear medicine
  • Q2b — Carrier-free / no-carrier-added radionuclides
  • Q3a — Thyroid uptake probe
  • Q3b — Personnel monitoring devices — TLD, OSL, pocket dosimeter
  • Q4 — PET MPI tracers (incl. F-18 flurpiridaz)
  • Q5 — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q6a — Radiotracer agents used in ventilation scan.
  • Q6b — RBC labelling — methods & factors
  • Q7 — FBP vs iterative reconstruction
  • Q8a — Ge-68/Ga-68 generator & Ga-68 radiochemistry
  • Q8b — Myocardial viability — techniques, tracers & PET protocol
  • Q9 — Brain tumours — PET/SPECT tracers & recurrence
  • Q10 — Sentinel node — radiopharmaceuticals & techniques

Paper III

  • Q1a — Discuss in brief the different SPECT and PET tracers used for imaging thyroid neoplasms.
  • Q1b — Discuss the management of medullary carcinoma thyroid.
  • Q2 — Graves' disease — management (adult & paediatric)
  • Q3a — Nuclear medicine in emergencies
  • Q3b — Urea breath test.
  • Q4 — RAI-refractory DTC — definition, diagnosis & management
  • Q5a — Response evaluation criteria — RECIST, PERCIST, EORTC
  • Q5b — TACE vs TARE / SIRT
  • Q6a — Lymphoma — PET/CT staging, Deauville & response
  • Q6b — NETPET score
  • Q7a — SUV — definitions & factors affecting
  • Q7b — GFR — plasma sample & other methods
  • Q8a — Tumour-induced osteomalacia
  • Q8b — Epilepsy — PET/SPECT & lesion imaging
  • Q9 — PRRT — principles, protocol, indications & adverse effects
  • Q10a — Neuroblastoma — imaging & management
  • Q10b — Management of Supraventricular Tachycardia.

Paper IV

  • Q1 — Radioactive waste disposal
  • Q2 — PSMA RLT trials — VISION, TheraP & ongoing trials
  • Q3a — RBE, OER & LET
  • Q3b — Acute radiation syndrome
  • Q4a — NM facility & high-dose therapy ward design (AERB)
  • Q4b — Transport of radioactive material — regulations, packages & TI
  • Q5a — Copper radionuclides (Cu-64/Cu-67) & copper theranostics
  • Q5b — PET MPI tracers (incl. F-18 flurpiridaz)
  • Q6 — Insulinoma & functional pancreatic NETs — imaging (incl. exendin)
  • Q6 — FAPI imaging & theranostics
  • Q7 — PET/MRI — clinical applications vs PET/CT
  • Q8a — FES (fluoroestradiol) PET
  • Q8b — Total-body / long axial FOV PET
  • Q9 — AI & machine learning in nuclear medicine
  • Q10 — Cardiac amyloidosis
DNB Nuclear Medicine June 202453 questions

Paper I

  • Q1 — Interaction of radiation with matter
  • Q2 — Alpha emitters & targeted alpha therapy
  • Q3 — Digital PET (SiPM)
  • Q4 — Gas-filled detectors — principle, regions & ionisation chamber
  • Q5 — Decay equation (N = N0e^-λt), half-life & mean life
  • Q6 — PET/CT quality control
  • Q7a — RCT & clinical trial design
  • Q7b — ROC curve
  • Q8 — Filters in nuclear medicine imaging
  • Q9a — Photoelectric & Compton effect
  • Q9b — RBE, OER & LET
  • Q10 — PET/MRI — clinical applications vs PET/CT
  • Q10 — CT & MRI — reconstruction & sequences

Paper II

  • Q1 — Re-188 generator & Re-188 radiopharmaceuticals
  • Q2 — Describe various long-lived positron emmiters whose half-lives are more than 2 hours with…
  • Q3 — Copper radionuclides (Cu-64/Cu-67) & copper theranostics
  • Q4 — Brain tumours — PET/SPECT tracers & recurrence
  • Q5 — Cardiac sarcoidosis imaging
  • Q6a–b — LAL & rabbit pyrogen tests
  • Q7 — Radiosynovectomy
  • Q8 — Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine)
  • Q9 — Insulinoma & functional pancreatic NETs — imaging (incl. exendin)
  • Q10a — Terbium-152.
  • Q10b — Hypoxia imaging

Paper III

  • Q1 — Define Three phase bone scintigraphy, procedure and indications. Is pin-hole imaging still…
  • Q2 — Renal scintigraphy in a patient after kidney transplant.
  • Q3a — Discuss various factors leading to False Positive and False Negative FDG PET/CT Imaging.
  • Q3b — SUV — definitions & factors affecting
  • Q4 — FAPI imaging & theranostics
  • Q5a — Thyroid nodule — Bethesda & TI-RADS
  • Q5b — TENIS — evaluation & management
  • Q6 — Gynaecological malignancies — PET/CT
  • Q7 — Sentinel node — radiopharmaceuticals & techniques
  • Q8 — Myocardial viability — techniques, tracers & PET protocol
  • Q9 — Dementia — FDG patterns (AD, DLB, FTD, rapidly progressive)
  • Q10a — Multiple myeloma — PET/CT
  • Q10b — Immuno-PET / antibody-based PET

Paper IV

  • Q1 — AJCC 8th edition — DTC staging changes
  • Q2a — Pb-212/Pb-203 & At-211 theranostics
  • Q2b — PRRT — principles, protocol, indications & adverse effects
  • Q3a — PROMISE Criteria.
  • Q3b — Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine)
  • Q4a — Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST
  • Q4b — Lymphoma — PET/CT staging, Deauville & response
  • Q5 — Bifunctional chelators
  • Q6a — Large-vessel vasculitis — PET (Takayasu, GCA, PETVAS)
  • Q6b — Cardiac amyloidosis
  • Q7 — PET/CT-guided biopsy & interventions
  • Q8a — HVL & TVL
  • Q8b — Radiation & tissue weighting factors (ICRP 60 vs 103)
  • Q9a — Copper radionuclides (Cu-64/Cu-67) & copper theranostics
  • Q9b — Radiation & tissue weighting factors (ICRP 60 vs 103)
  • Q10 — Biological dosimetry
DNB Nuclear Medicine December 202364 questions

Paper I

  • Q1 — Interaction of radiation with matter
  • Q2a — Decay equation (N = N0e^-λt), half-life & mean life
  • Q2b — Mediastinal nodal stations.
  • Q3 — Transient & secular equilibrium
  • Q4 — Gas-filled detectors — principle, regions & ionisation chamber
  • Q5a — Thesis protocol & ethics committee
  • Q5b — Lutetium-177 — production, decay scheme & uses
  • Q6a — Auger electrons & characteristic X-rays
  • Q6b — GM counter (incl. quenching)
  • Q7a — Radiation & tissue weighting factors (ICRP 60 vs 103)
  • Q7b — Distributions — Gaussian, Poisson, binomial
  • Q8 — RCT & clinical trial design
  • Q9a — Forest Plot.
  • Q9b — ROC curve
  • Q10a — Enumerate measures of variability and describe them.
  • Q10b — Cerenkov radiation & Cerenkov luminescence imaging

Paper II

  • Q1 — Collimators — types & principles (SPECT vs PET collimation)
  • Q2a — HVL & TVL
  • Q2b — Cyclotron — working, types (negative vs positive ion)
  • Q3 — Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine)
  • Q4a — Misadministration in nuclear medicine department and different steps undertaken to prevent it.
  • Q4b — Alpha vs beta vs Auger emitters for therapy
  • Q5 — QC of Tc-99m radiopharmaceuticals — radionuclidic & radiochemical purity
  • Q6 — FDG synthesis & quality control
  • Q7a — PET/CT-guided biopsy & interventions
  • Q7b — Personnel monitoring devices — TLD, OSL, pocket dosimeter
  • Q8a–b — Movement disorders & Parkinsonism — NM imaging
  • Q9 — MPI tracers — SPECT (Tl-201, Tc-99m MIBI/tetrofosmin)
  • Q10a — MTV & TLG
  • Q10b — Cardiac sarcoidosis imaging

Paper III

  • Q1 — RAI-refractory DTC — definition, diagnosis & management
  • Q2 — WHO classification & grading of NETs
  • Q2 — PRRT — principles, protocol, indications & adverse effects
  • Q3a — Pharmacological interventions in NM studies
  • Q3b — TARE / SIRT — indications, procedure & dosimetry
  • Q4 — Graves' disease — management (adult & paediatric)
  • Q5a — GI bleeding & Meckel's scintigraphy
  • Q5b — Paediatric UTI, VUR & DRCG
  • Q6a — IgG4-related disease — PET/CT
  • Q6b — Artefacts — SPECT, SPECT/CT & PET/CT
  • Q7a — Complex regional pain syndrome
  • Q7b — Gastric emptying & oesophageal transit
  • Q8a — Myocardial viability — techniques, tracers & PET protocol
  • Q8b — Painful limp (child / adult)
  • Q9a–b — Movement disorders & Parkinsonism — NM imaging
  • Q10a — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q10b — Large-vessel vasculitis — PET (Takayasu, GCA, PETVAS)

Paper IV

  • Q1 — Duties of the Radiological Safety Officer (RSO)
  • Q2 — Discuss the determinants and mechanisms of resistance for PSMA radioligand therapy in…
  • Q3a — Law of Bergonie and Tribondeau.
  • Q3b — INES — International Nuclear & Radiological Event Scale
  • Q4a — Transport of radioactive material — regulations, packages & TI
  • Q4b — Biological effects of radiation (somatic & genetic)
  • Q5a — INOCA & MINOCAl.
  • Q5b — COSMIC-311 trial
  • Q6a — FAPI imaging & theranostics
  • Q6b — Myocardial blood flow & flow reserve — PET quantification
  • Q7 — PET/MRI — clinical applications vs PET/CT
  • Q8a — Biological dosimetry
  • Q8b — Sentinel node — radiopharmaceuticals & techniques
  • Q9a — Rheumatology & myositis — PET/CT
  • Q9b — Reporting & data systems (RADS — PI-RADS, TI-RADS, etc.)
  • Q10a — Dementia — FDG patterns (AD, DLB, FTD, rapidly progressive)
  • Q10b — Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST
DNB Nuclear Medicine June 202369 questions

Paper I

  • Q1 — PET crystals — BGO, LSO, LYSO comparison
  • Q2a — CT & MRI — reconstruction & sequences
  • Q2b — Artefacts — SPECT, SPECT/CT & PET/CT
  • Q3 — SUV — definitions & factors affecting
  • Q4a — Thesis protocol & ethics committee
  • Q4b — Draw the diagrams of Nephron and Neuron labelling the parts.
  • Q5a — Pair production, Rayleigh scatter & photodisintegration
  • Q5b — Niel Bohr's atomic model with diagram.
  • Q6a — Auger electrons & characteristic X-rays
  • Q6b — Types of Neutron interactions with matter.
  • Q7a — Photoelectric & Compton effect
  • Q7b — Specific gamma-ray constant
  • Q7c — Linear energy transfer (LET) & Bragg peak
  • Q7d — Isomeric transition, internal conversion & electron capture
  • Q8a — Filters in nuclear medicine imaging
  • Q8b — Nyquist Frequency.
  • Q9a — Radiation & tissue weighting factors (ICRP 60 vs 103)
  • Q9b — CT & MRI — reconstruction & sequences
  • Q10a–b — Type I/II errors, null hypothesis & sample size

Paper II

  • Q1 — Methods of radionuclide production (reactor, cyclotron, generator)
  • Q2 — Gas-filled detectors — principle, regions & ionisation chamber
  • Q3 — Brain tumours — PET/SPECT tracers & recurrence
  • Q4 — Insulinoma & functional pancreatic NETs — imaging (incl. exendin)
  • Q5a — FDG synthesis & quality control
  • Q5b — CZT / solid-state cardiac cameras
  • Q6a — PET crystals — BGO, LSO, LYSO comparison
  • Q6b — 2D PET versus 3D PET - advantage and disadvantages of each acquisition method.
  • Q7a — Iodine-124
  • Q7b — Actinium-225 — decay scheme, production & nanogenerator
  • Q8a — Ge-68/Ga-68 generator & Ga-68 radiochemistry
  • Q8b — Lutetium-177 — production, decay scheme & uses
  • Q9 — Bone pain palliation radiopharmaceuticals
  • Q10a — FAPI imaging & theranostics
  • Q10b — Labelled leukocyte imaging (incl. FDG-WBC PET)

Paper III

  • Q1 — Large-vessel vasculitis — PET (Takayasu, GCA, PETVAS)
  • Q1 — Fever of unknown origin — PET/CT
  • Q2 — Pulmonary embolism — V/Q (planar vs SPECT) vs CTPA
  • Q3a — Preparations and precautions required for the high-dose radio-iodine therapy of a patient…
  • Q3b — AJCC 8th edition — DTC staging changes
  • Q4a — Breast cancer — staging & PET/CT (NCCN, LABC)
  • Q4b — Define thyroid storm and enumerate its clinical management.
  • Q5a — Cardiac stress — pharmacological & physical
  • Q5b — Diamox SPECT.
  • Q6a — Paediatric UTI, VUR & DRCG
  • Q6b — Gastric emptying & oesophageal transit
  • Q7a — GFR — plasma sample & other methods
  • Q7b — Peritoneal scintigraphy.
  • Q8a — Role of nucelar medicine in orthopaedic implant related complications evaluation. How does it…
  • Q8b — Movement disorders & Parkinsonism — NM imaging
  • Q9a — CT & MRI — reconstruction & sequences
  • Q9b — Contrast induced nephropathy (CIN).
  • Q10a — Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST
  • Q10b — Nephroprotection in PRRT

Paper IV

  • Q1 — Radioactive spill — containment & management
  • Q2 — Myocardial blood flow & flow reserve — PET quantification
  • Q3 — Multimodality imaging in the evaluation and management of Alzheimer's disease.
  • Q4a — AI & machine learning in nuclear medicine
  • Q4b — Ga-68 radiopharmaceuticals — range & applications
  • Q5a–b — Cardiac arrhythmias — SPECT & PET
  • Q6a — Role of PET in imaging of auto-immune encephalitis.
  • Q6b — NSCLC — molecular landscape & targeted therapy
  • Q7a — Response evaluation criteria — RECIST, PERCIST, EORTC
  • Q7b — PSMA RLT trials — VISION, TheraP & ongoing trials
  • Q8a — Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST
  • Q8b — Large-vessel vasculitis — PET (Takayasu, GCA, PETVAS)
  • Q9a — Acute radiation syndrome
  • Q9b — A recently married female, unaware of her pregnancy, received 5 mCi of I-131 activity…
  • Q10a — PET/CT-guided biopsy & interventions
  • Q10b — Axillary reverse mapping
DNB Nuclear Medicine December 202260 questions

Paper I

  • Q1 — Modes of radioactive decay
  • Q2 — Interaction of radiation with matter
  • Q3 — SPECT / SPECT-CT quality control (NEMA)
  • Q4a — Partial volume effect & recovery coefficient
  • Q4b — Beam hardening effect.
  • Q5a — Bremsstrahlung
  • Q5b — Actinium-225 — decay scheme, production & nanogenerator
  • Q6 — FBP vs iterative reconstruction
  • Q7a — Specific gamma-ray constant
  • Q7b — Attenuation correction (PET/CT, SPECT/CT, PET/MR)
  • Q8 — Collimators — types & principles (SPECT vs PET collimation)
  • Q9a — Tests of significance — t-test, chi-square, McNemar, ANOVA
  • Q9b — Kaplan Meier survival analysis.
  • Q10 — Discuss the various phases of clinical trial.

Paper II

  • Q1 — Radionuclide generators — principles & types (incl. PET generators)
  • Q1 — QC of Tc-99m radiopharmaceuticals — radionuclidic & radiochemical purity
  • Q2 — NET imaging — SPECT & PET tracers
  • Q3a — GM counter (incl. quenching)
  • Q3b — Dose calibrator — principle, QC & acceptance tests
  • Q4a — Intra-operative gamma probe
  • Q4b — Reactor-produced radionuclides
  • Q5a — Phantoms in nuclear medicine
  • Q5b — Solid-state / semiconductor detectors
  • Q6a — Personnel monitoring devices — TLD, OSL, pocket dosimeter
  • Q6b — Ga-68 radiopharmaceuticals — range & applications
  • Q7 — Thyroid uptake probe
  • Q8 — Transient & secular equilibrium
  • Q9a — Filters in nuclear medicine imaging
  • Q9b — Time-of-flight (TOF) PET
  • Q10 — RBC labelling — methods & factors

Paper III

  • Q1 — Infection & inflammation imaging — SPECT & PET tracers
  • Q2a — Diuretic renography & hydronephrosis / obstruction
  • Q2b — Pulmonary embolism — V/Q (planar vs SPECT) vs CTPA
  • Q3 — GI bleeding & Meckel's scintigraphy
  • Q4a — Cholecystagogues & interventions in hepatobiliary scintigraphy
  • Q4b — Quantitative PET parameters & factors affecting them
  • Q5a — Sports injuries
  • Q5b — Myocardial blood flow & flow reserve — PET quantification
  • Q6a — NETPET score
  • Q6b — F-18 FDOPA PET — clinical applications
  • Q7 — Brain tumours — PET/SPECT tracers & recurrence
  • Q8 — Prostate cancer — treatment options & radionuclide therapies
  • Q9 — Graves' disease — management (adult & paediatric)
  • Q10a — Bone pain palliation radiopharmaceuticals
  • Q10b — PRRT — principles, protocol, indications & adverse effects

Paper IV

  • Q1 — Internal dosimetry — MIRD & tumour dosimetry
  • Q2 — Death of a patient after high-dose I-131 — handling
  • Q3a — Acute radiation syndrome
  • Q3b — RBE, OER & LET
  • Q4a — Cardiac amyloidosis
  • Q4b — PET MPI tracers (incl. F-18 flurpiridaz)
  • Q5 — TKIs in thyroid cancer (incl. trials)
  • Q6a — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q6b — Movement disorders & Parkinsonism — NM imaging
  • Q7 — PET/MRI — clinical applications vs PET/CT
  • Q8 — Copper radionuclides (Cu-64/Cu-67) & copper theranostics
  • Q9a — Vascular imaging — atherosclerotic plaque & thrombus
  • Q9b — PSMA RLT trials — VISION, TheraP & ongoing trials
  • Q10a — Radiomics
  • Q10b — Tumour-induced osteomalacia
DNB Nuclear Medicine June 202255 questions

Paper I

  • Q1a — Working principle of SPECT Gamma Camera.
  • Q1b — SPECT / SPECT-CT quality control (NEMA)
  • Q2a–b — Interaction of radiation with matter
  • Q3a — Stochastic vs deterministic effects
  • Q3b — Scintillation detectors — principle & types
  • Q4 — HVL & TVL
  • Q5a — Tests of significance — t-test, chi-square, McNemar, ANOVA
  • Q5b — Distributions — Gaussian, Poisson, binomial
  • Q6 — Partial volume effect & recovery coefficient
  • Q7 — Cyclotron — working, types (negative vs positive ion)
  • Q8 — Alpha vs beta vs Auger emitters for therapy
  • Q9 — Attenuation correction (PET/CT, SPECT/CT, PET/MR)
  • Q10a — Physical, biological & effective half-life
  • Q10b — DICOM & PACS.

Paper II

  • Q1 — Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine)
  • Q2a–c — Sentinel node — radiopharmaceuticals & techniques
  • Q3a–b — Young hypertensive / hypertension — NM evaluation
  • Q4a — Radionuclide Cysternography.
  • Q4b — Salivary gland scintigraphy
  • Q5 — Paediatric UTI, VUR & DRCG
  • Q6a–b — Myocardial viability — techniques, tracers & PET protocol
  • Q7a — Epilepsy — PET/SPECT & lesion imaging
  • Q7b — Dementia — FDG patterns (AD, DLB, FTD, rapidly progressive)
  • Q8a — Adrenocortical imaging
  • Q8b — FDG synthesis & quality control
  • Q9a–c — Ge-68/Ga-68 generator & Ga-68 radiochemistry
  • Q10 — Radiopharmaceutical QC — physicochemical & biological tests

Paper III

  • Q1a–b — NET imaging — SPECT & PET tracers
  • Q2 — Multiple myeloma — PET/CT
  • Q3 — Response evaluation criteria — RECIST, PERCIST, EORTC
  • Q4a — Cholecystagogues & interventions in hepatobiliary scintigraphy
  • Q4b — Neonatal jaundice & biliary atresia — hepatobiliary scintigraphy
  • Q5a–c — Cardiac stress — pharmacological & physical
  • Q6a — Fever of unknown origin — PET/CT
  • Q6b — Infection & inflammation imaging — SPECT & PET tracers
  • Q7a–b — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q8 — I-131 MIBG therapy — neuroblastoma, protocol & complications
  • Q9a — TACE vs TARE / SIRT
  • Q9b — Pharmacological interventions in NM studies
  • Q10a–b — Hypoxia imaging

Paper IV

  • Q1a — PET/CT Enteroclysis: Indications, technique and advantages.
  • Q1b — Special techniques in PET/CT imaging in pelvic organ malignancies.
  • Q2a — F-18 FDOPA PET — clinical applications
  • Q2b — Angiogenesis imaging
  • Q3a — Positron emission mammography (PEM)
  • Q3b — CXCR4 / Pentixafor imaging
  • Q4 — ATA guidelines for thyroid cancer (2015 → 2025)
  • Q5 — AI & machine learning in nuclear medicine
  • Q6 — Redifferentiation of Radioiodine refractory differentiated thyroid cancer for reapplication…
  • Q7a — Immuno-PET / antibody-based PET
  • Q7b — Radioimmunotherapy (RIT)
  • Q8a — Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine)
  • Q8b — Role of External Radiation therapy in the management of thyroid cancer.
  • Q9 — Describe indications, advantages and disadvantages of Lu-177 PSMA-617 and Ac-225 PSMA-617 in…
  • Q10 — Labelled leukocyte imaging (incl. FDG-WBC PET)
DNB Nuclear Medicine December 202164 questions

Paper I

  • Q1 — Explain what is meant by binding energy of the nucleus. Explain the meaning of the terms:…
  • Q2a — Gas-filled detectors — principle, regions & ionisation chamber
  • Q2b — Dose calibrator — principle, QC & acceptance tests
  • Q3a — Annihilation coincidence detection & PET events (CTR)
  • Q3b — Noise equivalent count rate (NECR)
  • Q3c — PET crystals — BGO, LSO, LYSO comparison
  • Q4a — Enlist and discuss various non-imaging equipments used for patient study on day-to-day basis…
  • Q4b — Cyclotron — working, types (negative vs positive ion)
  • Q5a — Spatial resolution — FWHM & factors affecting it
  • Q5b — Phantoms in nuclear medicine
  • Q6a — Tests of significance — t-test, chi-square, McNemar, ANOVA
  • Q6b — Case-control study design
  • Q7a — Alpha emitters & targeted alpha therapy
  • Q7b — Actinium-225 — decay scheme, production & nanogenerator
  • Q8 — Methods of radionuclide production (reactor, cyclotron, generator)
  • Q9a–b — Decay equation (N = N0e^-λt), half-life & mean life
  • Q10a — Absorbed, equivalent & effective dose
  • Q10b — Stochastic vs deterministic effects

Paper II

  • Q1 — A young female is clinically and biochemically diagnosed as having Cushing's Syndrome. All…
  • Q2a — What is rhTSH? Discuss the approved indications of its use.
  • Q2b — What is Perchlorate discharge test? Why its use has been drastically reduced in current time?
  • Q3 — Phaeochromocytoma / paraganglioma — genetics & imaging
  • Q4a — TRODAT / DAT SPECT
  • Q4c — Molybedenum Breakthrough tests.
  • Q5a — Brain tumours — PET/SPECT tracers & recurrence
  • Q5b — FAPI imaging & theranostics
  • Q6a–b — Personnel monitoring devices — TLD, OSL, pocket dosimeter
  • Q7 — MPI tracers — SPECT (Tl-201, Tc-99m MIBI/tetrofosmin)
  • Q8 — Radionuclide generators — principles & types (incl. PET generators)
  • Q9a — Angiogenesis imaging
  • Q9b — Hypoxia imaging
  • Q9c — Testicular Imaging.
  • Q10 — Sentinel node — radiopharmaceuticals & techniques

Paper III

  • Q1 — What are the benign tumous of bone simulating malignancy? Discuss the role of Nuclear Imaging…
  • Q2a — Insulinoma & functional pancreatic NETs — imaging (incl. exendin)
  • Q2b — Role of PET/CT imaging in the management of Head & Neck squamous cell carcinomas.
  • Q3 — Hepatobiliary scintigraphy: Radiopharmaceuticals, clinical indications and advantages over…
  • Q4a — Cardiac stress — pharmacological & physical
  • Q4b — Epilepsy — PET/SPECT & lesion imaging
  • Q5 — Paediatric DTC — management (incl. pulmonary metastases)
  • Q6a — NET imaging — SPECT & PET tracers
  • Q6b — Radiosynovectomy
  • Q7a — GI bleeding & Meckel's scintigraphy
  • Q7b — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q8a — Multiple myeloma — PET/CT
  • Q8b — mCRPC — PET imaging & management
  • Q9a — FES (fluoroestradiol) PET
  • Q9b — TKIs in thyroid cancer (incl. trials)
  • Q10 — Graves' disease — management (adult & paediatric)

Paper IV

  • Q1 — PET/MRI — technology, configurations & physics
  • Q2 — Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST
  • Q3a — Amyloid & tau PET imaging
  • Q3b — Role of Nuclear Medicine in organ transplant evaluations.
  • Q4a — Positron emission mammography (PEM)
  • Q4b — Alpha emitters & targeted alpha therapy
  • Q5a — PET/CT-guided biopsy & interventions
  • Q5b — TARE / SIRT — indications, procedure & dosimetry
  • Q6a — Insulinoma & functional pancreatic NETs — imaging (incl. exendin)
  • Q6b — CXCR4 / Pentixafor imaging
  • Q7 — Lung NETs / carcinoids
  • Q8a — PET/CT in Radiotherapy Treatment Planning. What are its limitations?
  • Q8b — RAI-refractory DTC — definition, diagnosis & management
  • Q9 — I-131 MIBG therapy — neuroblastoma, protocol & complications
  • Q10 — Nephroprotection in PRRT
DNB Nuclear Medicine June 202159 questions

Paper I

  • Q1 — Describe the role of crystal thickness on intrinsic spatial resolution and sensitivity for…
  • Q2a–b — a) Methods of curve fittings. b) Explain Biexponential Curve fitting.
  • Q3a — Briefly describe the significance of: Slip ring technology.
  • Q3b — Digital PET (SiPM)
  • Q4 — Tests of significance — t-test, chi-square, McNemar, ANOVA
  • Q5 — PET/CT quality control
  • Q6 — Filters in nuclear medicine imaging
  • Q7a — Case-control study design
  • Q7b — RCT & clinical trial design
  • Q8 — Internal dosimetry — MIRD & tumour dosimetry
  • Q9 — Modes of radioactive decay
  • Q10 — Collimators — types & principles (SPECT vs PET collimation)

Paper II

  • Q1 — FDG synthesis & quality control
  • Q2 — What is the difference between radiochemical and radiopharmaceutical? Explain with example…
  • Q3a–b — Transport of radioactive material — regulations, packages & TI
  • Q3c — INES — International Nuclear & Radiological Event Scale
  • Q3d — Alpha vs beta vs Auger emitters for therapy
  • Q4 — Re-188 generator & Re-188 radiopharmaceuticals
  • Q5 — FAPI imaging & theranostics
  • Q6a — Nuclear medicine in emergencies
  • Q6b — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q7a — Enumerate and classify radiopharmaceuticals used for tumor imaging.
  • Q7b — F-18 FDOPA PET — clinical applications
  • Q8 — Recent advances in nuclear cardiology techniques.
  • Q9a — Methods of radionuclide production (reactor, cyclotron, generator)
  • Q9b — Carrier-free / no-carrier-added radionuclides
  • Q10 — I-131 & iodine isotopes — production & decay scheme

Paper III

  • Q1a — F-18 NaF PET
  • Q1b — Renal radiopharmaceuticals — glomerular vs tubular (DTPA, EC, MAG3)
  • Q2a — Role of Nuclear Medicine in the evaluation of drug addiction.
  • Q2b — RAI-refractory DTC — definition, diagnosis & management
  • Q3 — Describe the role of nuclear imaging in musculoskeletal diseases, particularly the non…
  • Q4a — Adrenocortical imaging
  • Q4b — WHO classification & grading of NETs
  • Q5 — Radioimmunotherapy (RIT)
  • Q6a–c — Dementia — FDG patterns (AD, DLB, FTD, rapidly progressive)
  • Q6d — Epilepsy — PET/SPECT & lesion imaging
  • Q7a — NSCLC — molecular landscape & targeted therapy
  • Q7b — Staging of Adenocarcinoma of prostate as per AJCC 8th Edition.
  • Q8 — Neonatal jaundice & biliary atresia — hepatobiliary scintigraphy
  • Q9a — Scintigraphic evaluation for the management of Tuberculosis.
  • Q9b — Clinical activity scores in the management of Graves' ophthalmopathy.
  • Q10 — Myocardial viability — techniques, tracers & PET protocol

Paper IV

  • Q1a — PSMA RLT trials — VISION, TheraP & ongoing trials
  • Q1b — COSMIC-311 trial
  • Q2 — PET/MRI — technology, configurations & physics
  • Q3a — Lessons learnt from Fukushima Nuclear Accident.
  • Q3b — Cyclotron-produced Technetium-99m - hype or hope in the era of frequent reactor short-downs.
  • Q4 — Intra-operative gamma probe
  • Q5a — Movement disorders & Parkinsonism — NM imaging
  • Q5b — Alpha emitters & targeted alpha therapy
  • Q6 — TKIs in thyroid cancer (incl. trials)
  • Q7a — Breast cancer — staging & PET/CT (NCCN, LABC)
  • Q7b — Triple-negative breast cancer
  • Q8 — Time-of-flight (TOF) PET
  • Q9a — Radio-receptor Imaging - strength and pitfalls.
  • Q9b — Digital PET (SiPM)
  • Q10a — Amyloid & tau PET imaging
  • Q10b — Discuss different types of cardiomyopathies. Describe Myocardial Perfusion SPECT in ischemic…
DNB Nuclear Medicine December 202057 questions

Paper I

  • Q1 — Personnel monitoring devices — TLD, OSL, pocket dosimeter
  • Q2a — Isomeric transition, internal conversion & electron capture
  • Q2b — Bremsstrahlung
  • Q3 — Attenuation correction (PET/CT, SPECT/CT, PET/MR)
  • Q4 — Time-of-flight (TOF) PET
  • Q4 — FBP vs iterative reconstruction
  • Q5 — Type I/II errors, null hypothesis & sample size
  • Q6a — Absorbed, equivalent & effective dose
  • Q6b — Radiation & tissue weighting factors (ICRP 60 vs 103)
  • Q7 — Interaction of radiation with matter
  • Q8 — Decay equation (N = N0e^-λt), half-life & mean life
  • Q8 — Transient & secular equilibrium
  • Q9a — Partial volume effect & recovery coefficient
  • Q9b — Spatial resolution — FWHM & factors affecting it
  • Q9c — HVL & TVL
  • Q9d — Linear energy transfer (LET) & Bragg peak
  • Q9e — Define the following: Branching Ratio.
  • Q10 — PET crystals — BGO, LSO, LYSO comparison

Paper II

  • Q1a — Brain tumours — PET/SPECT tracers & recurrence
  • Q1b — F-18 NaF PET
  • Q2a — LAL & rabbit pyrogen tests
  • Q2b — Swipe test.
  • Q3 — Radionuclide generators — principles & types (incl. PET generators)
  • Q4 — Bone pain palliation radiopharmaceuticals
  • Q5a — Parathyroid localisation — SPECT, PET (choline) & 4D-CT
  • Q5b — Prostate cancer PET/SPECT tracers (PSMA, choline, fluciclovine)
  • Q6 — Alpha emitters & targeted alpha therapy
  • Q7 — Bifunctional chelators
  • Q8 — Name various peptide-based radiopharmaceuticals and describe one in details.
  • Q9a — Insulinoma & functional pancreatic NETs — imaging (incl. exendin)
  • Q9b — Neuroblastoma — imaging & management
  • Q10 — Artefacts — SPECT, SPECT/CT & PET/CT

Paper III

  • Q1a — Sphincter of Oddi & gallbladder dyskinesia
  • Q1b — Lymphoscintigraphy & lymphoedema
  • Q2 — Movement disorders & Parkinsonism — NM imaging
  • Q3a — Complex regional pain syndrome
  • Q3b — Bone scintigraphy in: Diabetic foot.
  • Q4 — Thyroid cancer genetics & genomics
  • Q5 — Describe the causes of thyrotoxicosis. Discuss how to manage various thyroiditis.
  • Q6 — Role of PET/CT in staging and response assessment of non-small cell lung cancers.
  • Q7 — mCRPC — PET imaging & management
  • Q8 — Phaeochromocytoma / paraganglioma — genetics & imaging
  • Q9a — WHO classification & grading of NETs
  • Q9b — Lung NETs / carcinoids
  • Q10 — Recent WHO classification of brain tumors. Discuss molecular markers and their implication in…

Paper IV

  • Q1a–b — MTV & TLG
  • Q2 — Re-188 generator & Re-188 radiopharmaceuticals
  • Q3 — Alpha emitters & targeted alpha therapy
  • Q4 — Compare and contrast the multiparametric-MR versus nuclear imaging in prostate cancer.
  • Q5a — Amyloid & tau PET imaging
  • Q5b — Dementia — FDG patterns (AD, DLB, FTD, rapidly progressive)
  • Q6 — LV dyssynchrony
  • Q7 — Triple-negative breast cancer
  • Q8a — DLBCL vs. ALCL
  • Q8b — TACE vs TARE / SIRT
  • Q9 — RAI-refractory DTC — definition, diagnosis & management
  • Q10a–c — Epilepsy — PET/SPECT & lesion imaging
DNB Nuclear Medicine June 202061 questions

Paper I

  • Q1 — Mo-99 / Tc-99m — production & decay scheme
  • Q1 — Absorbed, equivalent & effective dose
  • Q2 — Transient & secular equilibrium
  • Q3 — Compartmental models, discuss with suitable radionuclide example.
  • Q4a — ICRP recommendations for dose limits for radiation professionals and general public.
  • Q4b — Radioactive spill — containment & management
  • Q5a–b — Scintillation detectors — principle & types
  • Q6a — ROC curve
  • Q6b — RCT & clinical trial design
  • Q7a — Solid-state / semiconductor detectors
  • Q7b — Specific gamma-ray constant
  • Q8 — Transport of radioactive material — regulations, packages & TI
  • Q9a — Auger electrons & characteristic X-rays
  • Q9b — Bremsstrahlung
  • Q9c — Cerenkov radiation & Cerenkov luminescence imaging
  • Q9d — Annihilation coincidence detection & PET events (CTR)
  • Q9e — Noise equivalent count rate (NECR)
  • Q10 — Describe embryology, normal and ectopic anatomical locations of parathyroids. What are the…

Paper II

  • Q1 — Thyroid uptake probe
  • Q2 — Routes of administration of radiopharmaceuticals with examples
  • Q3 — Radionuclide generators — principles & types (incl. PET generators)
  • Q4 — Quantitative PET parameters & factors affecting them
  • Q5 — FDG synthesis & quality control
  • Q6a — Ideal characteristics of therapeutic radionuclides.
  • Q6b — Amyloid & tau PET imaging
  • Q7a — Attenuation correction (PET/CT, SPECT/CT, PET/MR)
  • Q7b — Dead time & its correction
  • Q8 — Filters in nuclear medicine imaging
  • Q9a — Cardiac sarcoidosis imaging
  • Q9b — Myocardial viability — techniques, tracers & PET protocol
  • Q10 — Renal radiopharmaceuticals — glomerular vs tubular (DTPA, EC, MAG3)

Paper III

  • Q1 — Paediatric DTC — management (incl. pulmonary metastases)
  • Q2a — Bone scan findings in metabolic bone diseases.
  • Q2b — Salivary gland scintigraphy
  • Q3a — PRRT — principles, protocol, indications & adverse effects
  • Q3b — Nephroprotection in PRRT
  • Q4a — LV dyssynchrony
  • Q4b — Cardiac stress — pharmacological & physical
  • Q5a — Epilepsy — PET/SPECT & lesion imaging
  • Q5b — TRODAT / DAT SPECT
  • Q6 — Lymphoscintigraphy & lymphoedema
  • Q7 — Gynaecological malignancies — PET/CT
  • Q8a — Neonatal jaundice & biliary atresia — hepatobiliary scintigraphy
  • Q8b — Interventions in renal scintigraphy for renal artery stenosis.
  • Q9 — Immunotherapy response — pseudo/hyper-progression, iRECIST, iPERCIST
  • Q10 — TARE / SIRT — indications, procedure & dosimetry

Paper IV

  • Q1a — Stochastic vs deterministic effects
  • Q1b — Acute radiation syndrome
  • Q2 — Radioactive waste disposal
  • Q3 — Death of a patient after high-dose I-131 — handling
  • Q4 — Dose calibrator — principle, QC & acceptance tests
  • Q5a — Hospital Radiation safety committee.
  • Q5b — Delay Tank.
  • Q6 — TKIs in thyroid cancer (incl. trials)
  • Q7 — Role of Nuclear Medicine in stem cell imaging.
  • Q8a — Digital PET (SiPM)
  • Q8b — FAPI imaging & theranostics
  • Q9a — Total-body / long axial FOV PET
  • Q9b — AI & machine learning in nuclear medicine
  • Q10a — Radiomics
  • Q10b — Sentinel node — radiopharmaceuticals & techniques

Read 36 solved answers free

The free 90-page sample is taken straight from the printed DNB Nuclear Medicine volumes, with the book's own page numbers. It contains:

  • The Volume 1 cover, full index and high-yield list
  • Volume 1 answers on basic nuclear physics: binding energy, decay, equilibrium, interactions of radiation with matter, HVL and dose quantities
  • The Volume 2 cover, full index and high-yield list (clinical nuclear medicine, PET/CT oncology and radionuclide therapy)
  • Volume 2 answers on neurology and thyroid: amyloid and tau PET, dementia, thyroid imaging and more
Read the free sample (PDF)See the printed book
DNB Nuclear Medicine free sample, page 1DNB Nuclear Medicine free sample, page 3DNB Nuclear Medicine free sample, page 9DNB Nuclear Medicine free sample, page 17

Solved answers in the free sample

  1. Explain what is meant by binding energy of the nucleus. Explain the meaning of the terms:…Volume 1 · Part 1
  2. Niel Bohr's atomic model with diagram.Volume 1 · Part 1
  3. Auger electrons & characteristic X-raysVolume 1 · Part 1
  4. Isomeric transition, internal conversion & electron captureVolume 1 · Part 1
  5. I-131 & iodine isotopes — production & decay schemeVolume 1 · Part 1
  6. Mo-99 / Tc-99m — production & decay schemeVolume 1 · Part 1
  7. Modes of radioactive decayVolume 1 · Part 1
  8. Define the following: Branching Ratio.Volume 1 · Part 1
  9. Decay equation (N = N0e^-λt), half-life & mean lifeVolume 1 · Part 1
  10. Physical, biological & effective half-lifeVolume 1 · Part 1
  11. Transient & secular equilibriumVolume 1 · Part 1
  12. Interaction of radiation with matterVolume 1 · Part 1
  13. BremsstrahlungVolume 1 · Part 1
  14. Linear energy transfer (LET) & Bragg peakVolume 1 · Part 1
  15. Cerenkov radiation & Cerenkov luminescence imagingVolume 1 · Part 1
  16. Pair production, Rayleigh scatter & photodisintegrationVolume 1 · Part 1
  17. Photoelectric & Compton effectVolume 1 · Part 1
  18. Types of Neutron interactions with matter.Volume 1 · Part 1
  19. HVL & TVLVolume 1 · Part 1
  20. Specific gamma-ray constantVolume 1 · Part 1
  21. Amyloid & tau PET imagingVolume 2 · Part 6
  22. Dementia — FDG patterns (AD, DLB, FTD, rapidly progressive)Volume 2 · Part 6
  23. Multimodality imaging in the evaluation and management of Alzheimer's disease.Volume 2 · Part 6
  24. Movement disorders & Parkinsonism — NM imagingVolume 2 · Part 6
  25. TRODAT / DAT SPECTVolume 2 · Part 6
  26. Epilepsy — PET/SPECT & lesion imagingVolume 2 · Part 6
  27. Role of PET in imaging of auto-immune encephalitis.Volume 2 · Part 6
  28. Diamox SPECT.Volume 2 · Part 6
  29. Role of Nuclear Medicine in the evaluation of drug addiction.Volume 2 · Part 6
  30. Radionuclide Cysternography.Volume 2 · Part 6
  31. Discuss the iodine cycle in human body.Volume 2 · Part 7
  32. What is Perchlorate discharge test? Why its use has been drastically reduced in current time?Volume 2 · Part 7
  33. What is rhTSH? Discuss the approved indications of its use.Volume 2 · Part 7
  34. Graves' disease — management (adult & paediatric)Volume 2 · Part 7
  35. Clinical activity scores in the management of Graves' ophthalmopathy.Volume 2 · Part 7
  36. Define thyroid storm and enumerate its clinical management.Volume 2 · Part 7

Frequently asked questions

How many DNB Nuclear Medicine previous-year questions are there?

This page lists 297 DNB Nuclear Medicine theory questions from 12 exam sessions, June 2020 to December 2025, arranged in 18 parts. Repeated questions are listed once, with every paper and year in which they were asked.

Which DNB Nuclear Medicine topics are asked most often?

Parathyroid localisation — SPECT, PET (choline) & 4D-CT (8×); Myocardial viability — techniques, tracers & PET protocol (8×); FAPI imaging & theranostics (8×); PET crystals — BGO, LSO, LYSO comparison (7×); Tests of significance — t-test, chi-square, McNemar, ANOVA (7×).

Where can I find solved answers to these DNB Nuclear Medicine questions?

Every question on this page is answered in full in our printed DNB Nuclear Medicine solved previous-year questions, written from Mettler & Guiberteau 7e, The Requisites 5e, Saha's Fundamentals of Nuclear Pharmacy 7e, Cherry, Sorenson & Phelps 4e and the IAEA Nuclear Medicine Physics handbook.

Is there a free sample of the answers?

Yes. A free 90-page sample with full answers from the book is available: read the free sample (PDF).

How should I use these questions to prepare for the DNB Nuclear Medicine exam?

Start with the most-asked list, since repeated topics come back often. Then work through the topic-wise list part by part, and use the session-wise list to practise complete papers against the clock.

Get every answer in print

DNB Nuclear Medicine: 297 solved answers in two volumes, printed, bound and delivered anywhere in India.

See the book